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Abstract
Osteosarcoma (OS) is the most common highly malignant primary solid bone-tumor.
Despite its relatively low incidence rate among overall cancers, it remains one of the most harmful
primary malignant tumors in childhood and adolescence. Although some tumor markers like
mutant p53 can be potentially used as biomarker to detect OS, its extensive association with the
clinical outcome is poorly understood. The establishment of a methodology to identify patient with
early stage of OS remains to be investigated. It is now evident that serum autoantibodies against
tumor-associated antigens (TAAs) could be used as serological cancer biomarkers in types of
cancers, which derives from the notion that anti-TAA autoantibodies are considered as
immunological “sentinels” underlying molecular events associated with tumorigenesis. New
insights into molecular and cellular biology and the differential diagnosis of cancers have also been
obtained. Moreover, customized TAA arrays significantly increase sensitivity/specificity and
provide a great promise for the early detection of cancer, monitoring cancer progression, discovery
of novel therapeutic targets, and designing personalized therapeutic interventions.
During the past decade, proteomic approaches, such as serological proteome analysis
(SERPA), have been used to identify the repertoire of immunoreactive proteins in various diseases.
Recent several years, we have used this approach to extensively screen sera from patients with
certain types of cancer such as hepatocellular carcinoma (HCC), esophageal squamous cell
carcinoma (ESCC), Prostate Cancer (PCa) and Lung Cancer (LC), and sera from patients with precancer conditions such as liver fibrosis to identify and characterize the potential TAAs.
We used SERPA to profile anti-TAA autoantibody responses in sera from patients with
Osteosarcoma (OS), and Normal Human, and explore differences of these responses. This
approach can detect autoantibodies to TAAs that could serve as clinical biomarkers and
immunotherapeutic agents. Sera from OS, Osteochondroma (OC) and Normal Human Sera (NHS)
were probed by immunoblotting against cellular proteins extracted from U2-OS and Saos-2 cell
lines, with OS sera showing stronger immunoreactivity. MALDI-TOF/TOF Mass Spectrometry
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(MS) analysis of immunoreactive protein spots revealed that several OS sera contained
autoantibodies to a number of proteins, particularly to alpha-enolase (ENO1). Analysis of 172
serum samples from patients with OS, OC and NHS by Enzyme-Linked Immunosorbent Assay
(ELISA) showed higher frequency of anti-ENO1 autoantibodies in OS sera compared to others.
Interestingly, descant of ENO1 immunoreactivity was observed in most patients after treatments,
which may imply a potential association between anti-ENO1 autoantibody titers and disease
progression. The expression of ENO1 in Osteosarcoma tissues was evaluated by
immunohistochemistry (IHC) in Tumor Microarray (TMA). We observed the cumulative positive
rate of autoantibodies against seven selected TAAs identified from SERPA (ENO1, NPM1,
GAPDH, TPI1, HSP60, PDLIM1, STMN1) in OS reached 90.4%, significantly higher than that in
normal control sera. These results support the central hypothesis of this proposed project that
"customized" TAA arrays constitute promising and powerful tools for enhancing the serological
detection of OS. Together, our intriguing findings demonstrate that ENO1 is one of autoantigens
that elicit autoimmune responses in OS and can be used as biomarkers in immunodiagnosis and
progression of OS.

Key Words: Osteosarcoma (OS), Tumor-associated antigen (TAA), Serological proteome
analysis (SERPA), Alpha-enolase, Cancer early detection, Immunodiagnosis.
Running Title: Immunoseroproteomic profiling in human Osteosarcoma.
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Chapter 1: Introduction
Osteosarcoma (OS), characterized by the production of osteoid material by malignant
osteoblastic cells, is the most common highly malignant primary bone-tumor deriving from
primitive bone-forming mesenchymal cells1. Nevertheless, it is, like all other sarcomas, a low
incidence rate less than 1% of all cancers diagnosed in the United States 2. The American Cancer
Society estimates that approximately 1,000 new cases arise in the USA each year and about 400
of these are in children and teens. In addition, OS is the most frequent bone cancer occurring in
children and adolescents aged 10–20 years3. Despite its relatively low incidence rate among overall
cancers, OS is highly malignant and can be often neglected on misidentification with benign
lesions or trauma contributing to fatal consequences since the initial symptoms of the disease are
commonly quite nonspecific and subtle in onset, and furthermore, it progresses aggressively and
approximately 20% of patients with OS have detectable metastases at diagnosis usually developing
in the lung4-7. It remains one of the most harmful primary malignant tumors in childhood and
adolescence, responsible for a high rate of amputation, disability and death. Current OS therapies
are inadequate, with five year survival rate of ~60% even after pre- and post-operative neoadjuvant chemotherapy and excision of operable lesions8. Moreover, tumor size and metastases
detectable at diagnosis always portend a worse outcome5,9. Thus, a critical need in the diagnosis
and management of OS is to determine an optimal combination of clinical biomarkers that could
detect tumors early with high specificity/sensitivity and with limited invasiveness, and that could
accurately predict which diagnosed patient will develop aggressive tumors requiring treatment.
Over the last few decades, many studies demonstrated that these autologous cells
developing to tumors contain self-antigens and its abnormal exposure or presentation of these
antigens recognized by the immune system, and further trigger the production of autoantibodies
that have been generally termed anti-TAA autoantibodies against these cellular antigens. This
notion has come from evidence that anti-TAA autoantibodies are immunological “sentinels”
underlying molecular events associated with tumorigenesis10-12. What is more, they exhibit
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increased levels in very early stages of carcinogenesis13 and are observed stable with high level in
patients’ sera despite low levels of the corresponding antigens14 or even after removal of these
antigens15,16. Such benefits of these autoantibodies have triggered a growing enthusiasm for
applying these autoantibodies against tumor-associated antigens (TAAs) as serological cancer
biomarkers. Moreover, recent years have seen an enormous increase in efforts to humoral
immunity to TAAs for addressing specific clinical issues such as the potential utility of TAAs and
anti-TAA autoantibodies systems as cancer biomarker tools for the early detection of cancer,
monitoring cancer progression, discovery of novel therapeutic targets, and designing personalized
therapeutic interventions17.
At present, the emerging studies of the molecular markers or pathways on OS have denoted
these molecules as a key role in OS tumorigenesis and prognostication, which may be exploited to
predict specific outcomes such as the likelihood of diagnosis or micrometastases at diagnosis and
response to chemotherapy. In addition, these pathways could also be potential targets for new OS
chemotherapeutic agents. However, in spite of the availability of a plethora of genes and their
protein products like HER218, p5319, HSPs20, which may be considered as OS biomarkers, it is
widely recognized that their uses with the available clinical information is still insufficient for
early cancer diagnosis and for guiding individualized therapeutic interventions and predicting
outcomes. As recent advances in proteomic technology have thrust the bone cancer field into the
era of proteomic approaches to the identification of serum biomarkers for the early, non-invasive
diagnosis of cancer and for monitoring tumor progression. One approach includes direct profiling
of human cancer sera, using two-dimensional gel electrophoresis (2-DE) system and mass
spectroscopy, to identify distinctive protein signatures characteristic of different tumor types6,2124

. A second approach, which is the focus of this dissertation, is the exploitation of the serum

autoantibody repertoire from cancer patients for the identification of TAAs and the design of
customized TAA arrays for the serological diagnosis and management of OS25,26.
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1.1

Osteosarcoma

1.1.1 Epidemiology and etiology
In spite of primary bone cancer, bone is one of the most common sites for tumor metastasis,
in particular for breast and prostate cancers, and bone metastases are frequently associated with
intractable bone pain, pathological fractures, nerve compression and hypercalcemia due to
osteolysis27. Approximately 1,500 new sarcomas of bone are recorded in the USA per year while
93,000 new cases of lung carcinoma and 88,000 new cases of breast carcinoma are diagnosed 8.
Among various types of bone tumors, OS is the most frequent highly malignant bone-tumor
comprising about 20% of primary bone sarcomas. Although it is a low incidence rate less than 1%
of all cancers diagnosed in the USA2, approximately 1,000 new cases arise each year. The
incidence of OS has always been considered to be higher in males than in females 28and it was a
rate of 5.4 per million persons per year in males while 4.0 per million in females according to the
recent Surveillance, Epidemiology, and End Results (SEER) data in 200829. With respect to
ethnicity, the more recent date from SEER indicate that OS occurs more frequent in Asians/Pacific
Islander and in Hispanics28.
There are two age-specific peaks in frequency in OS. Most of these occur in young patients,
with a peak manifestation during the second and third decade of life. The two types of malignant
bone cancers that predominate in children and adolescents are osteosarcoma and Ewing sarcoma,
which represent about 56% and 34% of bone cancers, respectively30. In the United States,
approximately 400 new cases of OS are diagnosed younger than 20 years old annually, coinciding
with the pubertal growth spurt30. The second peak, slightly increasing from the fourth decade, has
its top after the sixth decade. And cases of primary conventional osteosarcoma may arise in older
patients, but as age increases, secondary osteosarcoma is more likely. Such tumors develop in
patients who have had a preexisting lesion or disease in the bone, such as Paget disease and
radiation-induced sarcomas disease31. The diagnosis of secondary OS shows significance in terms
of prognosis and expected response to treatment; secondary OS does not respond well to
chemotherapy and has a worse outcome than that of primary conventional osteosarcoma31.
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OS can appear in any bone, while the most common sites are near the metaphyseal growth
plates of the long bones of the extremities. It frequently localizes in the femur (42%, with 75% of
these tumors in the distal femur), the tibia (19%, with 80% of these tumors in the proximal tibia),
and the humerus (10%, with 90% of these tumors in the proximal humerus)32.
To date, the etiology of OS is still largely unknown, however a number of linkage studies
have implicated an interaction of environmental insults and genetic susceptibility. Several studies
demostrate the etiology of OS involves epidemiologic and environmental factors, and genetic
impairments. Currently, the limited well-known risk factors associated with the development of
OS comprise ionizing radiation, alkylating agents, Paget’s disease, hereditary retinoblastoma, the
Li–Fraumeni familial cancer syndrome, and other chromosomal abnormalities32. Among them,
exposure to radiation is the only proven exogenous risk factor but with a long interval (10–20
years)33. Additionally, OS can also develop in response to genetic predisposition conferred by RB1
or tumor protein p53 mutations. For example, RB1 mutations predispose to OS in the teen years,
long after an infant’s retinoblastoma is cured. Cumulative OS incidence following retinoblastoma
has been estimated as 7% at 20 years34,35. Discoveries regarding the etiology of osteosarcoma will
enable patients to avoid the causes and prevent its occurrence, however, presently the causes of
OS are not completely known. Therefore, the molecular pathways or markers of OS will
potentially reveal the forming and developing of OS, which also promises some new effective
treatments for this disease.
1.1.2 Diagnosis
With the advancing modern treatment protocols that combine chemotherapy and surgery
in the last two decades, although survival rate increased from 10-20% up to 60-70%, there is still
a need for convincing early detections and efficient therapeutic alternatives in case of nonresponders to chemotherapy, relapsed patients and patients with metastasis. In fact, more than 30%
of patients with OS will succumb to metastatic disease36. Clinically, the diagnosis of OS requires
a combination of clinical presentation, radiologic studies, and pathologic tissue evaluation. The
4

initial clinical symptom of OS is frequently pain in the affected area, which may also be associated
with localized soft tissue swelling or limitation of motion in the adjacent joint. Pain usually occurs
after strenuous exercise or a trauma and usually lasts for around 3 months before diagnosis with
progressing over time, and commonly following with swelling with a hard painful mass in the
affected region1. However, the initial symptoms of the disease are often quite nonspecific and
subtle in onset, which often does not draw the patient’s attention. Most OS are diagnosed at a
relatively advanced stage of the disease during which the presence of sclerosis and the malignant
nature of the disease are clearly evident5. In addition, the typical radiographic features have been
extensively illustrated, but diagnosis is frequently overlooked when the tumor presents as a variant
or early in its development. Rarely, however, OS may be detected before aggressive features are
manifested on radiographs, and such OS can be neglected on misidentification with benign lesions4
or trauma6. Beyond the clinical symptoms and radiographs, the histological examination of the
biopsy specimens is still preferred by many orthopedic oncologists for the diagnosis of OS. Despite
its invasive procedure and burdens to the patients, the accuracy of diagnosis may vary among
different sample collections and different observers, making the clinical prediction questionable.
Additionally, inappropriately performed biopsies are a frequent cause of misdiagnosis, amputation
and local recurrence, and are associated with reduced survival8. As a result more emphasis should
be placed on early diagnosis not only attempting to deliver effective chemotherapy to small
localized disease but also crucially important to reduce the extent of local resection minimizing
disability enhancing the long-term survive rate and improving the quality of life of patients37.
Furthermore, such limitations of the current diagnosis approach have been suggested that a critical
unmet need in the diagnosis and management of OS is the development of reliable non-invasive
biomarkers for early diagnosis of OS.
1.1.3 Classification and staging
OS can be divided into two major categories: primary tumors that occur de novo in
otherwise normal bone, comprising the most common OS: conventional OS (also called classic,
5

intramedullary or central), and secondary tumors that develop in abnormal bone in the setting of a
preexisting benign lesion, irradiated bone, retinoblastoma, or Paget disease of bone32.
Conventional OS has three histologic subtypes: fibroblastic, chondroblastic, and osteoblastic OS.
In all three subtypes, there is production of osteoid (immature bone matrix) by malignant spindleshaped sarcoma cells31.
Staging is classified based on the aggressive grade and the extensive and the spread levels
of OS. According to the Musculoskeletal Tumor Society Staging System38 and Enneking System39,
which are widely used in clinical, tumor stages have been classified based on tumor grade (I, low
grade; II, high grade), tumor extension (A, intraosseous involvement; B, extraoesseous extension)
and the presence of distant metastases (III)38, as reported in Table 1. Most conventional OSs
present as stage IIB tumors which is non-metastatic tumor with an associated soft tissue mass39.
Table 1: Surgical staging of bone sarcomas38.
Stage

Grade

Site

Metastasis

IA

Low

Intracompartmental

No

IB

Low

Extracompartmental

No

IIA

High

Intracompartmental

No

IIB

High

Extracompartmental

No

III

Any

Any

Regional or distant

Definitions: I, low grade; II, high grade; A, intraosseous involvement; B,
extraoesseous extension, III, the presence of distant metastases.
The more recent version (the seventh edition) of the American Joint Committee on Cancer
(AJCC) staging system is similar to the MTS Staging System, but it incorporates into the system
the size of the tumor and the presence of skip metastases40 (Table 2). Additionally, it more
specifically subdivided stages I and II into A and B categories depending on tumor size being
greater or less than 8 cm in any dimension, rather than intra- or extra-compartmental. Moreover,
6

it has the extra stage IV which is divided into IV-A, describing pulmonary metastases, and IV-B,
describing other metastases.
Table 2: American Joint Committee on Cancer staging system for bone tumors40.
Stage

Tumor

Nodes

Metastasis

Grade

IA

T1

N0

M0

G1, 2 low grade, GX

IB

T2

N0

M0

G1, 2 low grade, GX

T3

N0

M0

G1, 2 low grade, GX

IIA

T1

N0

M0

G3, 4 high grade

IIB

T2

N0

M0

G3, 4 high grade

III

T3

N0

M0

G3, 4

IVA

Any T

N0

M1a

Any G

IVB

Any T

N1

Any M

Any G

Any T

Any N

M1b

Any G

Definitions: T1, tumor 8 cm or less in greatest dimension; T2, tumor more than 8 cm in greatest
dimension; T3, discontinuous tumors in the primary bone site; N0, no regional lymph node
metastasis; N1, regional lymph node metastasis; M0, no distant metastasis; M1a, lung; M1b, other
distant sites; G1, well differentiated (low-grade); G2, moderately differentiated (low-grade); G3,
poorly differentiated; G4, undifferentiated; GX, grade cannot be assessed.
1.1.4 Treatment
The 5-year survival rate of patients with OS was 10–20% before the 1970s when treatment
was mainly limb amputation41. Due to the rapid development of surgical techniques and the
application of radiotherapy and/or effective systemic chemotherapy over the past thirty years,
approximately two-thirds of children with non-metastatic OS are cured with the combination of
surgery and chemotherapy, which has made limb salvage procedures a safe alternative to
amputation and led to an increase in disease-free and overall survival rates39,42. Generally, after
initial diagnosis, patients usually receive multi-agent preoperative chemotherapy and then surgical
7

extirpation of the primary tumor in the affected bone followed by postoperative chemotherapy43.
The response of the preoperative chemotherapy is measured by the extent of necrosis in the
resected tumor, which is considered as good when ≥90% tumor necrosis could be found whereas
response is considered as poor when <90% tumor necrosis are found44. However, unfortunately,
in spite of modifications in postoperative chemotherapy, the poor responders to the preoperative
chemotherapy often associate with have a worse outcome and a high risk of developing metastasis
compared to patients who have a good response to chemotherapy43. In fact, the long term survival
rate of these poor responders has not been improved in the past 30 years45. Therefore, it is essential
to develop a novel focus on identification of diagnostic and prognostic indicators to detect these
resistant tumors as early as possible, so that more aggressive therapy can be used upfront to
improve the outcomes.
1.2

Tumor-associated antigens (TAAs) and anti-TAAs autoantibodies
It is now evident that cancer sera comprise autoantibodies that react with a unique group

of autologous cellular antigens called TAAs10,46,47. The types of cellular proteins that induce these
autoantibody responses are quite varied and include the tumor suppressor p5348,49, oncogene
products such as HER-2/neu and ras50, proteins that protect mRNAs from degradation such as
p6251 and CRD-BP52, onconeural antigens53, differentiation-antigens such as tyrosinase and the
cancer/testis antigens54, and anti-apoptotic proteins such as surviving55 and LEDGF56. Elements
contributing to produce such autoantibodies are not fully understood but the available studies
believe that many of the target antigens are cellular proteins whose aberrant regulation or
overexpression could lead to tumorigenesis, such as p5348,49. In terms of the mRNA binding
protein p62, known as a fetal protein absent in adult tissues, immunogenicity appears to be related
to abnormal expression of p62 in tumor cells57. The immune system in certain cancer patients
appears to have the capability of sensing these abnormalities in self-antigens and responding by
producing autoantibodies58. An emerging concept is that autoantibodies associated with a specific
type of cancer are directed against aberrantly regulated or activated protein components of
8

molecular pathways involved in the malignant transformation process in that particular type of
cancer59. Taken together, anti-TAAs autoantibodies might be regarded as reporters implying
aberrant cellular mechanisms in tumorigenesis10. In recent years, research on humoral immunity
to TAAs has received significant attention, and investigators are now beginning to address specific
clinical questions such as the potential utility of TAA-autoantibody systems as early cancer
biomarker tools to monitor therapeutic outcomes, or indicators of disease prognosis17.
1.3

Tumor-Associated Antigens (TAAs) in OS
Albeit the reports concerning the repertoire and function of TAAs in OS are still limited,

growing evidence suggests that these tumors might express several diagnostic and/or therapeutic
targets. The numerous TAAs summarized in Table 3 have been described in previous studies. In
human OS, HER2/erbB-2 is overexpressed in 40-45% and correlates with poor prognosis, early
pulmonary metastases and poor response to preoperative chemotherapy60,61. Although expression
of the p53 protein has been reported in OS, unexpectedly, the following several studies did not
find a specific correlation between p53 expression and the clinical outcome, suggesting that p53
fails as a marker for OS19,62. Several previous reports had shown that P-glycoprotein expression
may associated with an increased risk for chemotherapy resistance63-66. Afterwards, HSP27 was
reported that the overexpression in human OS is related with poor prognosis67. Sudo et al.
suggested that melanoma-associated antigen (MAGE) family members are expressed in substantial
numbers of OS as tumor-rejection antigens in a major histocompatibility class-I-restricted
manner68. And in sarcoma cell lines, HSP72 has been shown to be selectively expressed on their
cell surface thereby overcoming protection and acting as the target for natural killer cells69, which
correlates with a good response to neoadjuvant chemotherapy70. The GD2 ganglioside was found
overexpressed in OS71 and later, some groups demonstrated that anti-GD2 antibody therapy
improves survival in high-risk neuroblastoma72. Two tumor-rejection antigens SART173 and
SART374 were reported to be expressed in OS, in which the results suggest that these proteins and
their derived peptides could be molecules appropriate for use in specific immunotherapies for
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HLA-A24+ patients with OS or malignant fibrous histiocytosis. The homogeneous expression of
the B7-H3 (8H9 antigen) on cell membrane makes it an attractive candidate for targeted
immunotherapy75. Additionally, the human METCAM/MUC18 (melanoma antigen/MUC18), a
cell adhesion molecule, was shown overexpressed in OS, and played a central role in the metastasis
of OS and suggested that targeted inhibition of this antigen by ABX-MA1 might be a novel
immunotherapeutic approach in the management of OS76. Furthermore, this study also concluded
that anti-MUC18 antibodies could inhibit the development of OS metastases in a preclinical
model76. In the past few years, association of CXCR4 expression with initial metastases77, SAA
associated with type of tumor and high-risk OS development45 and CLUAP1 potentially useful as
a prognostic/diagnostic marker for OS78 has been suggested. Jacobs et al. reported that all 9 OS
tissue samples expressed MAGE-1, 2, 8, and 8 of 9 expressed NYESO-1, cancer testis antigens or
cancer germline genes, in their cancer germline gene expression in pediatric solid tumors studies79.
Like the other tumors, survivin is also overexpressed in OS as an anti-apoptotic molecule, and
several investigators has revealed that survivin overexpression is associated with poor clinical
outcome and it may be used as an independent predictor of survival for OS patients80. More
recently, Maehara et al. showed that the level of midkine expression, known as a heparin-binding
growth factor midkine, correlates with the prognosis of patients with OS, and anti-midkine
functional antibodies effectively inhibit growth of OS cells in vitro81.
In the recent past, several studies have attempted to identify novel targets for
immunotherapy exploiting humoral and cellular immune responses against OS, although their
precise role in cell biology remains unclear. Among them, two serological antigens OSAA-3 and
OSAA-5 were identified exclusively by serum from OS patients but not by serum from normal
individuals, implying that the immune responses to these two antigens were OS-associated82.
Papillomavirus binding factor (PBF) was identified by derived cDNA library screening with
autologous tumor-reactive CD8+T cells, which was overexpressed in most OS and might
contribute to peptide-based vaccination and/or adoptive antigen-specific T-cell therapy of patients
with OS and other bone and soft tissue tumors83. The report by Rouleau et al. showed that low
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level of endosialin/tumor endothelial marker 1 (TEM1) in normal tissues and the high levels
measured in several sarcoma subtypes, suggesting that TEM1 may be a suitable target protein for
selective therapeutic intervention84. In more recent years, the researchers found that interleukin 11
receptor alpha (IL11Rα)85 and fibroblast activation protein (FAP)86 were selectively expressed in
OS patients compared with healthy groups indicating that they may play roles in tumor
development and progression in OS.
On the other hand, the recognition that human tumors stimulate the production of
autoantibodies against TAAs has opened a new chapter in cancer biology focusing on the
possibility that autoantibodies could be exploited as serological tools for the early diagnosis and
management of cancer25. The autoantibody titers against HSP60 have been reported to be increased
in patients with OS but no correlation with clinical performance was found 87. One year later, the
other group reported that such immunoreactivity against HSP90 might be of predictive value in
human OS since the presence of anti-HSP90 autoantibodies correlates with a good response to
neoadjuvant chemotherapy and their absence correlates with the occurrence of metastase88.
Upon the current limited information, it seems that the autoantibodies in OS appear to be
directed preferentially against proteins that participate in tumorigenesis and are highly expressed
in bone tumors. Unfortunately, many published studies on TAA identification have failed to further
detail this association. Additionally, since no molecular diagnostic and/or prognostic markers have
yet been clinically established, risk stratification is largely based on the initial stage of the disease
and on the response to chemotherapy. It would be essential to develop a novel focus on
identification of diagnostic and prognostic indicators to detect these resistant tumors as early as
possible, so that more aggressive therapy can be used upfront to improve the outcomes.
Table 3: Identification of TAAs or anti-TAA autoantibodies in OS analyzed in multiple
studies.
Target
antigens

Description

Observation in OS

Ref.

HER2

Oncogene

Correlates with poor prognosis
for patients with OS.

60,61
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P53

Tumor suppressor

Pglycoprotein

ATP-binding cassette (ABC)
transporters
Heat shock protein 27, protein
chaperone and antioxidant

HSP27

MAGE

HSP72
GD2
SART1,
SART3

B7-H3
Melanoma
antigen
MUC18
CXCR4

SAA

CLUAP1

MAGE 1,2,8
NY-ESO-1

Melanoma antigen family A
Heat shock protein 70 family and
a chaperone protein
Disialoganglioside GD2, a sialic
acid-containing glycosphingolipid

Fails as a maker in OS because
of no significant correlation
between p53 expression and the
clinical outcome and response to
chemotherapy.
Increased risk for chemotherapy
resistance.
Correlates with poor prognosis
for patients with OS.
Expressed in substantial
numbers of OS in a major
histocompatibility class-Irestricted manner.
Correlates with a good response
to neoadjuvant chemotherapy.
Overexpressed in OS.

Potentially used in specific
immunotherapies HLAA24+ patients with OS or
malignant fibrous histiocytosis.
Potential molecules for use in
58 KD glycosylated tumorspecific immunotherapies for
associated protein antigen
HLA-A24+ patients with OS or
malignant fibrous histiocytosis.
MCAM (melanoma cell adhesion
Correlates directly with tumor
molecule) and as CD146
progression and metastatic
(endothelial antigen)
potential.
Potentially used as a prognostic
Chemokine receptor type 4, an
factor and as a predictor of
alpha-chemokine receptor
potential metastatic
development in OS.
Serum amyloid A, a family
Increased SAA levels associated
of apolipoproteins associated
with type of tumor and high-risk
with high-density lipoprotein (HDL) OS development.
Potentially used as a
prognostic/diagnostic marker
Clustering associated protein 1
and/or for a target of
immunotherapy of OS.
Melanoma-associated antigen
Expressed MAGE-1, 2, 8 in all 9
(MAGE)
OS tissue samples.
New York esophageal squamous
Expressed NY-ESO-1 in 8 of 9
cell carcinoma 1 (NY-ESO-1), a
OS tissue samples.
cancer-testis antigen
Squamous cell carcinoma antigen
recognized by T cells, tumorrejection antigens
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19,62

63-66

67

68

69,70

71,72

73,74

75

76

77

45

78

79

79

Survivin
Midkine
OSAA-3
and OSAA5

PBF

TEM1

IL-11Rα

FAP
Anti-HSP60
antibody
Anti-HSP90
antibody
Anti-MUC18
antibody
Anti-midkine

1.4

Potentially used as an
Inhibitor of apoptosis
independent predictor of
survival for OS patients.
Correlates with the prognosis of
Heparin-binding growth factor
patients with OS.
Potentially used as candidates
Unknown
for diagnosis and targets for
immunotherapy in OS.
May contribute to peptide-based
vaccination and/or adoptive
Papillomavirus binding factor (PBF) antigen-specific T-cell therapy
of patients with OS and other
bone and soft tissue tumors.
Tumor endothelial marker 1
Potentially used as a target
(TEM1), prototypical member of a
protein for selective therapeutic
family of genes expressed in the
intervention.
stroma of tumors.
May represent a new therapy for
Interleukin-11 receptor alpha-chain patients with OS pulmonary
metastases.
Might be considered as a novel
Fibroblast activation protein
therapeutic target against this
cancer.
Increases of anti-HSP60
Autoantibodies against heat shock
antibodies at the time of first
protein 60
diagnosis of OS.
Correlates with a good response
Autoantibodies against heat shock
to neoadjuvant chemotherapy
protein 90
and their absence correlates with
the occurrence of metastases.
Inhibits the development of OS
Autoantibody against MUC18
metastases in a preclinical
model.
Inhibits growth of OS cells in
Autoantibody against midline
vitro.

80

81

82

83

84

85

86

87

88

76

81

Identification of TAAs
The study of the humoral response to infectious diseases and chronic diseases, such as

cancer, is important for many reasons, including understanding the host response to disease,
identification of protective antigens, vaccine development, and discovery of biomarkers for early
diagnosis and prognosis. While several approaches have been used during the past decades for the
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identification of TAAs, the most successful have been the serological screening of cDNA
expression libraries and phage display libraries and more recently proteomics-based approaches.
One of the approaches is the utilization of serum antibodies from cancer patients to immunoscreen
cDNA expression library to identify TAAs in cancer, and some of these identified TAAs may have
potential diagnostic and prognostic values in cancer. In early studies, we examined sera from
cancer patients by Western blotting, using extracts of cultured tumor cells as source of antigens,
or by indirect immunofluorescence on fixed tumor cells. Using these techniques we identified sera
with high-titer reactivity to putative TAAs, and subsequently used the antibodies in these sera to
isolate antigen DNA sequences from cDNA expression libraries (Fig. 1). In this manner, several
novel TAAs, including p6251 and p9089 were identified in our previous studies. Subsequently,
several novel, as well as previously defined TAAs90 were identified with cancer sera using a
methodology called SEREX (Serological analysis of recombinant cDNA expression libraries),
which is essentially a modification of a previous method91. The rationale behind SEREX is that
intracellular proteins which are involved in carcinogenesis are provoking autoantibody responses
and therefore autoantibodies can be used to immunoscreen cDNA expression libraries to isolate,
identify and characterize proteins that might potentially be involved in malignant transformation
(Fig. 2). In cases of OS, novel as well as previously defined TAAs have been identified using the
SEREX method, including CLUAP1 78, OSAA-3 and OSAA-5 82.
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Figure 1: TAAs identification exploiting cDNA expression library immunoscreening. In brief,
the sera from cancer patients were initially examined using extracts of cancer culture cells as
source of antigens in Western blotting and by indirect immunofluorescence (IIF) on whole cells.
With these two techniques, we identify sera which have high-titer fluorescent staining or strong
signals to cell extracts on Western blot and subsequently use the antibodies in these sera to isolate
cDNA clones from cDNA expression libraries. Additionally, the isolate positive clones were
performed by mass spectrometry to further confirm the results from cDNA expression library
screening.
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Figure 2: Serological analysis of recombinant cDNA expression libraries (SEREX)92.

1.5

Cancer immunoseroproteomics
As recent advances in proteomic technology have thrust the bone cancer field into the era

of proteomic approaches to the identification of serum biomarkers for the early, non-invasive
diagnosis of cancer and for monitoring tumor progression. One approach includes direct profiling
of human cancer sera, using two dimensional gel electrophoresis (2-DE) system and mass
spectroscopy, to identify distinctive protein signatures characteristic of different tumor types 6,2124

. Previously, we provided one of the first examples of the characterization and validation of the

protein biomarker signature of primary bone cancer by using SELDI-TOF-MS to profile sera from
OS patients with and without bone metastases and a cluster of unique proteins in the profile of
patients with bone metastases were identified as discrete isoforms of SAA45. A second approach,
focused in our current studies, is the exploitation of the serum autoantibody repertoire from cancer
patients for the identification of TAAs and the design of customized TAA panels or arrays for the
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serological diagnosis and management of OS25,26. This approach has been termed as “serological
proteome analysis” (SERPA)93.
Our previous studies have demonstrated that the SERPA approach can be applied to many
models of disease. Recent several years, we have used this approach to extensively screen sera
from patients with certain types of cancer such as hepatocellular carcinoma (HCC)94 and
esophageal squamous cell carcinoma (ESCC)95, Prostate Cancer (PCa)96,97 and Lung Cancer
(LC)98,99 and sera from patients with pre-cancer condition such as liver fibrosis100 to identify and
characterize the potential TAAs. In our laboratory, this protocol was developed specifically for
screening immune sera to support the development and characterization of TAAs. A brief
description of the SERPA approach we have used to identify and characterize TAAs is shown in
Fig.3. Briefly, the sera from cancer patients were initially examined using extracts of culture cells
as the source of protein antigens in One-dimensional gel electrophoresis (1-D) Western blotting
and by indirect immunofluorescence (IIF) on whole cells. With these two techniques, we identified
sera that have high-titer fluorescent staining or strong signals to cell extracts on (1-D) Western
blotting and narrow the targeting proteins on specific molecular weight bands, and subsequently
used the antibodies in these sera as probes in a proteomic approach to isolate potential TAAs. Cell
extracts of cultured cancer cells was applied onto the first dimension isoelectrofocusing gel (1DIEF), and subsequently loaded onto the second-dimension gel (2DE-SDS-PAGE). The proteins
were transferred to the nitrocellulose membrane or visualized by Coomassie blue staining (or silver
staining). After immunoblotting (2-DE Western blotting) with cancer sera and benign tumor sera
or normal human sera (as controls), a number of protein spots of interest were excised from the 2DE gels, digested by trypsin, and subsequently analyzed by mass spectrometry (MS). In
subsequent studies, we will use several approaches such as Enzyme-linked Immunosorbent Assay
(ELISA), 1-D Western blotting and immunohistochemistry (IHC) with tissue arrays to
comprehensively characterize and validate the identified the TAAs and anti-TAA autoantibodies
systems that are potentially useful in cancer immunodiagnosis, and then evaluate the sensitivity
and specificity of different antigen-antibody systems as markers in certain type of cancer for
17

further developing “TAA array” systems for cancer diagnosis, prediction, and for following the
response of patients to treatment.
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Figure 3: Schematic representation of identification and validation of TAAs using serological
proteome analysis (SERPA) approach. In brief, the sera from OS patients and controls were
initially examined using extracts of culture cells as source of antigens in Western blotting and by
indirect immunofluorescence (IIF) on whole cells. With these two techniques, we identify sera
which have high-titer fluorescent staining or strong signals to cell extracts on Western blotting and
narrow the targeting proteins on specific molecular weight bands, and subsequently use the
antibodies in these sera as probes in immunoproteomic screening. Cell extracts of cultured human
cells was also applied onto the first dimension gel (isoelectrofocusing gel), and subsequently
loaded onto the second-dimension gel (2-DE-SDS-PAGE). The proteins were transferred to the
nitrocellulose membrane or visualized by silver staining or Coomassie brilliant blue staining. After
immunoblotting with OS sera and control sera, a number of protein spots of interest were excised
from the 2-DE gels, digested by trypsin, and subsequently analyzed by mass spectrometry (MS).
In subsequent studies, we will characterize the identified cellular proteins that are potential
biomarkers in OS.

1.6

TAA mini-arrays and cancer immunodiagnosis
Interest in the use of anti-TAA autoantibodies as serological markers for cancer diagnosis

derives from the recognition that these antibodies are generally absent, or present in low frequency
in normal individuals and in non-cancer conditions26. Their persistence and stability in the serum
of cancer patients is an advantage over other potential markers, including the TAAs themselves,
which are released by tumors but rapidly degraded or cleared after circulating in the serum for a
limited time59. Furthermore, the widespread availability of methods and reagents to detect serum
autoantibodies facilitates their characterization in cancer patients and assay development.
However, compared with autoimmune diseases, where the presence of a particular autoantibody
may have diagnostic value, cancer-associated autoantibodies, when evaluated individually have
little diagnostic value. This is mainly due to their low frequency, sensitivity, and specificity. Such
drawback has been observed in our previous study and we found it can be overcome by using miniarrays of properly selected TAAs, and that different types of cancer may require different TAA
arrays to achieve the sensitivity and specificity required to make immunodiagnosis a feasible
adjunct to tumor diagnosis end even prognosis47.
Our pioneering findings provide evidence that detection of autoantibodies in cancers can
be substantially enhanced by using a mini-array of several TAAs as target antigens47,101,102. For
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instance, this mini-array comprised 14 full-length recombinant proteins expressed from cDNAs
encoding surviving, CAPERα, RalA, p62, Koc, MDM2, cyclin B1, p53, 14-3-3ζ, p90, IMP1, cMyc, NPM1 and p16 was customized for detection of HCC. The antibody frequency to any of
these individual TAA was variable, ranging from 5.6% to 21.1% in HCC103. However, with the
successive addition of TAAs to a final total of 14 TAAs, there was stepwise increase of positive
antibody reactions up to 69.7% in HCC103. The fact is that antibodies to any individual antigen
such as anti-p53, anti-p62 or anti-c-Myc do not reach levels of sensitivity which could become
routinely useful in diagnosis47,101-103. These data indicate that the combination of multiple TAAs
might yield higher sensitivity for serological diagnosis of cancer. On the other hand, the data also
suggest that in the selection of different TAA-antibody systems, some of the TAAs may tum out
to be more specific for a certain type of cancer. It is conceivable that specific autoantibody profiles
can be identified with the help of customized TAA arrays and that the results could be beneficial
for differential diagnosis of specific types of cancer.
1.7

Dissertation project hypothesis
Our previous studies have showed that detection of autoantibodies in cancer patients can

be substantially improved exploiting mini-arrays of selected TAAs as target antigens. These
studies support the central hypothesis of this proposed project that "customized" TAA arrays
constitute promising and powerful tools for enhancing the serological detection of OS.
Implementation of TAA arrays in immunoscreening programs for cancer diagnosis, or as tools for
monitoring cancer progression and guiding therapeutic interventions, requires maximizing their
sensitivity and specificity. This can be achieved through the identification of novel TAAs and
design of optimal TAA arrays to discriminate serologically OS from benign bone tumors or other
cancers and diseases.
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1.8

Dissertation project specific aims and rationale
1.

Identify and characterize novel TAAs in OS using SERPA approach. The rationale is

that intracellular proteins involved in bone carcinogenesis provoke autoantibodies that can be used
as probes in proteomic analysis to isolate, identify, and characterize potential oncoproteins.
2. Validate the potential value of novel identified TAAs as OS biomarkers. This will be
achieved by: a) Determine whether the autoantibodies to the TAAs identified in Aim 1 are specific
to serum from OS patients with different clinical stages or are also detected in serum from patients
with the related but benign Osteochondroma (OC) and normal individuals, and b) examining the
expression of the TAAs in clinical bone tissue specimens and a panel of bone cell lines.
3.

Design customized TAA mini-arrays that could be used to enhance autoantibody

detection in OS. The sensitivity and specificity of these arrays will be tested against OS sera,
benign bone tumors or other cancers and controls.
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Chapter 2: Materials and Methods
2.1

Serum samples
Nighty five serum samples from 52 OS patients including 24 patients with serial serum

samples collected at least two to five samples obtained at the time of diagnosis and at different
time points along the disease progression. All samples are collected through IRB-approved
protocols from the two collaborative institutions, namely Henan Luoyang OrthopedicTraumatological Hospital (HLOH) in China and Institutional Human Subject Review Boards of
the University of Texas at El Paso, after informed consent had been signed. These samples were
used to create proteomic profiles and evaluate targeted TAAs. Twenty-eight serum samples from
age-matched anonymized OC patients was also from HLOH were used as benign bone tumor
controls. We chose age-matched OC as a benign control because it is the most common benign
bone tumor and these samples were readily available in our study. In terms of controlling for
potential impact of nonspecific host response on serum proteomic profiles, OC patients are
probably more appropriate than normal subjects because both OS and OC patients share primary
tumors that have similar anatomic location and tissue type. In addition, 49 age and sex matched
normal serum samples from normal human donors were collected from HLOH annual physical
examination in people with no clinical evidence of OS as well. The normal donor serum samples
were pooled used as a normal control in 2-DE Western blotting and individually tested in 1-D
Western blotting. After collection of the whole blood, allow the blood to clot by leaving it
undisturbed at room temperature. This usually takes 15-30 minutes. Remove the clot by
centrifuging at 1,000-2,000 ×g for 10 minutes in a refrigerated centrifuge. The serum supernatant
is collected and divided into aliquots and stored at -80 oC until use.
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Table 4: Characteristics of patients with Osteosarcoma (OS), Osteochondroma (OC) and
Normal Human (NH)
OS (n=52)

OC (n=28)

NH (n=49)

24.7, 14.2
4-64

17.2, 12.0
4-52

24.0, 13.1
4-59

36 (69.2)
16 (30.8)

19 (67.9)
9 (32.1)

31 (63.3)
18 (36.7)

Age
Mean, SD
Range
Gender (%)
Male
Female
Clinical stage (%)
Stage I-II
Stage III-IV
Unknown
Histologic type (%)
Osteoblastic
Fibroblastic
Osteoblastic
Others
Anatomic site (%)
Femur
Tibia
Fibula
Knee
Others
Tumor size (%)
<5 cm (%)
≥5 cm (%)
Grade (%)
1
3
Unknown

2.2

38 (73.1)
10 (19.2)
4 ( 7.7)
36 (69.2)
6 (11.5)
4 (7.7)
6 (11.5)
27 (51.9)
15 (28.8)
3 (5.8)
3 (5.8)
4 (7.7)
16 (30.8)
36 (69.2)
42 (80.8)
4 (7.7)
6 (11.5)

Cell line and cell extracts
U2-OS (ATCC® HTB-96TM) and Saos-2 (ATCC® HTB-8TM) cell lines were purchased

from the American Type Culture Collection (Manassas, VA) and culture following the specific
protocol as provided. The cell lines were maintained in a humidified atmosphere with 5% CO2 at
37 oC using the supplier’s prescribed ATCCformulated McCoy's 5A Medium Modified (Cat#
30-2007), supplemented with fetal bovine serum (FBS) to a final concentration of 15%, and 100
units/mL penicillin and 100 units/mL streptomycin. Cells grown in 175-cm2 Falcon tissue culture
flasks were allowed to reach 80-90% confluence. Then, cells were rinsed once with McCoy's 5A
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without FBS and removed from the flask by incubating them with a solution containing trypsinEDTA (Cat# 25200056, Gibco, Carlsbad, CA), and harvested in a 15 mL centrifuge tube for further
study. U2-OS and Saos-2 cells are lysed directly in 1X Laemmli’s sample buffer (Cat# 1610737,
Bio-Rad, Hercules, CA) and boiled each cell lysates in sample buffer at 100°C for 5 min. Lysates
can be aliquoted and stored at -20°C for future use.
2.3

Identified recombinant proteins and antibodies
Purified ENO1 protein (Cat# E-6126, Sigma-Aldrich, St. Louis, Missouri) was acquired

from Sigma. Full length protein GAPDH (ab77109), TPI1 (ab100826), HSP60 (ab78430),
PDLIM1 (ab177676) and STMN1 (ab87492) were purchased from AbcamInc (Cambridge, MA).
Commercially available antibodies used in this study included mouse anti-beta actin (Cat# sc4778, Santa Cruz Biotechnology, CA, 1:1000 dilution), goat anti-mouse IgG-HRP (Cat# sc-2005,
Santa Cruz Biotechnology, CA, 1:5000 dilution), rabbit polyclonal antibody to ENO1 (Cat#
A1033, Neo Scientific, Cambridge, MA).
2.4

Expression and purification of identified recombinant proteins
NPM1 construct GFP-NPM1 WT (plasmid ID: 17578) from Addgene Inc. (Cambridge,

MA, USA) was subcloned into the pET28a vector to express the fusion protein with N-terminal
6×His tags. The recombinant NPM1 protein expressed in Escherichia coli BL21 (DE3) was
purified using nickel column chromatography.
2.5

One-dimensional gel electrophoresis (1-D) and Western blotting analysis
To screen the autoantibody-positive sera, U2-OS and Saos-2 cells were lysed directly in

1X Laemmli’s sample buffer and boiled for 10 min. After the removing of the insoluble fraction
by centrifuge, samples were loaded onto 4–15% Mini-PROTEAN®TGX Stain-FreeTM Protein
Gels (Cat# 4568081, Bio-Rad, Hercules, CA), which was then transferred onto 0.45 µm
nitrocellulose membrane (Cat# 16201115, Bio-Rad, Hercules, CA) for Western blotting. The
membrane was stained with Ponceau S to confirm the transfer efficacy of the proteins and then the
membrane was cut into 0.1-inch wide stripes. After blocking with 3% nonfat milk prepared in 1×
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Phosphate Buffered Saline (PBS), containing 0.05% Tween-20 (PBST), for 1h at RT, the
nitrocellulose membrane was incubated with sera at a dilution of 1:200 with 1.5% nonfat milk in
1× PBST. Goat anti-human IgG-HRP (Cat# sc-2453, Santa Cruz Biotechnology, CA, 1:10000
dilution) was used as secondary antibody with a dilution of 1:10000 with 1.5% nonfat milk in 1X
PBST for 30 min at RT. The positive bands were detected with SuperSignal™ West Pico
Chemiluminescent Substrate (Prod# 34080, Thermo Fisher Scientific Inc., IL). Quantitative
assessment of band molecular weight was performed by Image Lab statistical software (Bio-Rad,
CA, USA).
2.6

Indirect immunofluorescence (IIF) microscopy
Indirect immunofluorescence assay was performed on HEp-2 antinuclear antigen tissue

slides (Cat# AN-1012, MBL, Des Plaines, IL). Normal human sera and PBS were used as negative
and blank controls, respectively, and Sjogren's Syndrome A Control (SS-A) human sera was used
as positive control. The sera were diluted at 1:40 in PBS, pH 7.4 and incubated with the slides for
30 min at RT. After extensive washing, the slides were incubated with Goat Anti-Human IgG
(H+L) Secondary Antibody, FITC (Cal# H10301, Thermo Fisher Scientific Inc., IL) as secondary
antibody diluted 1:1000 in PBS for 1h at RT. The slides were washed three times with PBS before
adding a drop of mounting media containing 1.5 µg/mL 4’,6’-diamidino-2-phenylindole (DAPI)
(Cal# H-1200, Vector Laboratories Inc. Burlingame, CA) to prevent photobleaching. The slides
were then examined under fluorescence microscopy, Leica DM1000 (Leica Microsystems,
Houston, TX), at 400×magnification. Images were acquired using the software QCapture 290.1
(Qimaging, Burnaby, BC, Canada). All images were acquired under identical conditions.
Ambiguous results were considered negative. The immunostaining patterns is compared for
consistency

with

available

experimental

gene/protein

characterization

data

in

the

UniProtKB/Swiss-Prot database and other experimental evidence for location described in
scientific literature104,105.
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2.7

Two-dimensional gel electrophoresis (2-DE) and Western blotting analysis
U2-OS and Saos-2 cells were directly lysed in rehydration sample buffer (8M Urea, 50

mM dithiothreitol (DTT), 4% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate
(CHAPS), 0.2% carrier ampholytes) as provided by Bio-Rad Laboratories (Cat# 1632106, BioRad, Hercules, CA) and were vortexed vigorously for 90 mins at room temperature (RT). Insoluble
substances were removed by centrifuge at 16,000×g or 30 min at 4 °C. Supernatant was collected
and protein concentration was measured by the Bradford Protein Assay (Cat# 500-0201, Bio-Rad,
Hercules, CA). For the first dimensional gel electrophoresis (1D-IEF) analysis, a total of 200 μg
protein was mixed with rehydration buffer containing a trace bromophenol blue prepared in
proteomics-grade water and applied on a pH 3−10, 7-cm isoelectric focusing (IEF) strip (Cat# 1632002, Bio-Rad, Hercules, CA). IEF was performed at a current of 50 mA per gel, 300 V for 30
min, followed by 8000 V for 2.5 h, and additional 8000 V for 5 h. Strips were immediately stored
at −80 °C for the second dimensional gel electrophoresis (2-DE) analysis. For the second
dimensional electrophoresis, 15% SDS polyacrylamide gels (SDS-PAGE) were used. Proteins
were transferred onto nitrocellulose membrane for 2-DE Western blotting analysis or stained with
0.1% Coomassie blue R-250 prepared in 40% methanol/10% acetic acid. The spots were visualized
using PD Quest 2-DE analysis software (Bio- Rad Laboratories, Hercules, CA) as described in the
manufacturer’s manual and also in our previous study94,95,100.
2.8

Serological proteomic analysis (SERPA)
For 2-DE Western blotting, the proteins on 2-DE gel were directly transferred into

nitrocellulose membrane and following the same protocol as described above. A schematic
representation of protein biomarker identification in OS is summarized in Fig 3. Membrane was
stained with Ponceau S to confirm the transfer efficacy of the proteins and several reference circles
were drawn around prominent protein bands/spots on the stained nitrocellulose membranes to
serve as orientation and alignment marks. These marks were essential for accurate digital overlay
of immunoreactive spots in the film of the nitrocellulose membrane (from analysis 2DE gel)
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probed with human sera with corresponding protein spots in the Coomassie-stained reference 2DE gel. Molecular weight markers on the sides of the 2D gels also facilitated the alignment. The
reference and analysis 2-DE gels were run in the same apparatus under identical conditions to
ensure accurate alignment of protein spots. After blocking with 3% nonfat milk prepared in 1×
PBS, containing 0.05% Tween-20 (PBST), for 1h at RT, the nitrocellulose membranes were
incubated with 11 representative OS sera and a pool of 5 NHS used as control at a dilution of 1:200
with 1.5% nonfat milk in 1× PBST. Goat anti-human IgG-HRP (Cat# sc-2453, Santa Cruz
Biotechnology, CA, 1:10000 dilution) was used as secondary antibody with a dilution of 1:10000
with 1.5% nonfat milk in 1X PBST for 30 min at RT. The positive bands were detected with
Enhanced Chemiluminescence (ECL) substrate (Thermo Fisher Scientific Inc., IL).
2.9

Sample preparation for mass spectrometry (MS)
The targeted gel sports were excised from a Coomassie blue-stained preparative gel and

then washed with HPLC grade water, followed by destained with acetonitrile (ACN) for 15 mins
to remove Coomassie blue staining, and dried in a vacuum centrifuge (Vacufuge, Eppendorf,
Westbury, NY) as described previously106. After the reduction (with 5 mM DTT) of disulfide
bounds and alkylation (with 10mM iodoacetoamide) of cysteine residues, digestion will be
performed by addition of 12.5 ng/µL of sequencing-grade trypsin (Promega, Madison, WI) in 50
mM ammonium bicarbonate containing 5 mM CaCl2. Following the enzymatic digestion overnight
at 37oC, the peptides will be extracted with 25mM ammonium bicarbonate in 50% ACN, followed
by 5% formic acid (FA) in 50% ACN solution. After removal of acetonitrile in a vacuum centrifuge
(Vacufuge, Eppendorf, Westbury, NY), the sample will be desalted by C18 bead ziptips (POROS
R2, Applied Biosystems, Framingham, MA)107, and dried out by in a vacuum centrifuge before
mass spectrometry analysis.
2.10

Identification of candidate TAAs by mass spectrometry (MS)
MS and MS/MS data for protein identification were obtained by using a MALDI-TOF-

TOF instrument (5800 proteomics analyzer; Applied Biosystems). Instrument parameters were set
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using the 4000 Series Explorer software (Applied Biosystems). The MS spectra were recorded in
reflector mode in a mass range from 800 to 4000 with a focus mass of 2000. The TOF/TOF
calibration mixtures (AB SCIEX) were used to calibrate the spectrum to a mass tolerance within
10 ppm. The MS spectra were processed using TOF-TOF Series Explorer software (V4.0, AB
SCIEX), At least 1,000 laser shots were typically accumulated with a laser pulse rate of 400 Hz in
the MS mode, whereas in the MS/MS mode spectra up to 2,000 laser shots were acquired and
averaged with a pulse rate of 1,000 Hz. For MS calibration, autolysis peaks of trypsin
([M+H]+842.5100 and 2,211.1046) were used as internal calibrates, and the most intense ion
signals (up to 10) were selected as precursors for MS/MS acquisition, excluding the trypsin
autolysis peaks and the matrix ion signals.
2.11

Protein identification
Peptide mass finger printing (PMF) and MS/MS queries were performed by using the

MASCOT search engine 2.2 (Matrix Science, Ltd.) embedded into GPS-Explorer Software 3.6
(Applied Biosystems) on the database of NCBI_Triticum (downloaded on 3/4/2015; 51829
sequences) and UniProt_viridiplantae (downloaded on 4/72015; 2872433 sequences) with the
following parameter settings: 100 ppm mass accuracy, trypsin cleavage one missed cleavage
allowed, carbamidomethylation set as fixed modification, oxidation of methionine was allowed as
variable modification, MS/MS fragment tolerance was set to 0.4 Da. A GPS Explorer protein
confidence index ≥ 95% were used for further manual validation.
2.12

Enzyme-linked immunosorbent assay (ELISA)
ELISA procedures were performed essentially as indicated in previous studies51,102,108,109.

Briefly, purified recombinant proteins were diluted in PBS to a final concentration of 1.0 μg/ml
and coated onto a Clear Flat-Bottom Immuno Nonsterile 96-Well Plates (Cal# 3455, Thermo
Fisher Scientific Inc., IL), which were then incubated overnight at 4 °C. Human sera diluted at
1:100 were incubated in the antigen-coated wells. Goat anti-Human IgG (H+L) Secondary
Antibody, HRP (Cal#H10307, Thermo Fisher Scientific Inc., IL,1:4000 dilution) and the substrate
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(1 mg/ml 2,2-azino-bis [3-ethylbenzthiazoline-6-sulfonic acid] with 0.005% hydrogen peroxide in
citrate buffer, pH 4.6) were used as detecting reagents. The optical density (OD) was measured at
405 nm using an automated plate reader (SpectraMax 190; Molecular Devices, Sunnyvale, CA).
All serum samples were assayed in duplicate and all positive sera were further confirmed by
Western blotting.
2.13

Immunohistochemistry (IHC)
Immunohistochemical study was performed using commercially available bone disease

spectrum and normal bone tissue microarray (TMA) (Cat# OS802a&BO244d, US Biomax, Inc.)
Osteosarcoma and chondrosarcoma tissue microarray contains 51 cases of osteosarcoma, 27
chondrosarcoma, plus 2 bone marrow tissue, and single core per case. And normal bone tissue
microarray contains 11 cases of bone tissue, 1 osteosarcoma, and duplicate cores per case. The
tissues were deparaffinized, endogenous peroxide was blocked in 3% hydrogen peroxide in
methanol, and microwave antigen retrieval was done using a Trilogy Pretreatment Solution (Cat#
920P-10, Cell Marque, Rocklin, CA). Blocking was done using Avidin/Biotin blocking kit (Cat#
928B-00, Cell Marque, Rocklin, CA) and TMA slides were incubated with polyclonal anti-ENO1
antibody at concentration (1:200 dilution). Biotinylated secondary antibody, CytoScan™ HRP
Detection System (Cat# 951D-10, Cell Marque, Rocklin, CA), and DAB Substrate Kit (3,3’diaminobenzidine) were used as detecting reagents (Cat# 957D-20, Cell Marque, Rocklin, CA).
The tissues were counterstained with hematoxylin (Cat# 930D-10, Cell Marque, Rocklin, CA),
fixed by Richard-Allan Scientific™ Signature Series Bluing Reagent (Cal# 7301, Thermo
Fisher Scientific Inc., IL) and dehydrolyzed with different concentration of ethanol and
Citrisolvent. Finally, the slides were mounted with permount mounting medium and observed
under brightfield microscopy (Leica LDM7000, S/N393985, Leica Microsystems Inc., US).
Briefly, five representative 100X and 400X magnification fields for each patient were randomly
selected for histology evaluation. Positive rate (PR) and staining intensity (SI) were used to
describe the expression based on the number and staining intensity of positively-stained cells in
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the tissue samples. The sum of positive rate core and staining intensity score was used to estimate
the antigen expression in each sample, in which the final score, <4 was defined as low/negative
expression, whereas ≥4 was defined as high/positive expression110. The protein expression was
compared for consistency with available experimental gene/protein characterization data in types
of cancers from the Pathology Atlas105,111.
2.14

Function analysis of differentially expressed proteins
Gene ontology (GO) annotation was performed to better understanding the biological

functions of these differentially expressed proteins. Go over-representation test of the selected
genes (corresponding to the identified proteins by SERPA from U2-OS and Sao-2 cell lines) were
performed by using the cluster Profiler package against genome annotation for human
(org.hs.eg.db) database in R (version 3.4.2)112,113. Only GO from genes with e-value ≤1e-10 for
database search was accepted.
2.15

Statistical analysis
Data regarding the different immunoreactivity of the sera were summarized by mean of

OD value. Due to the sera autoantibodies against some TAAs were not normally distributed,
nonparametric Mann-Whitney U tests were used to compare differences of autoantibody levels
between two groups, and nonparametric Kruscal-Wallis test were used to compare differences of
antibody levels among multiple groups. χ2 tests were used to compare the differences of frequency
between two groups and among multiple groups. Related-samples Wilcoxon signed rank test was
employed to analyze the serial assay of anti-ENO1 autoantibody by ELISA along the disease
progression. The receiver operating characteristic (ROC) analysis of single-variable was
conducted for each anti-TAA for the distinguishing of OS from controls, leading to estimates of
area under the curve (AUC) with 95% confidence interval (CI). The optimal cut-off value (CV)
for the optical density (OD) of an ELISA for determining a positive reaction was designated as the
mean absorbance of the NHS controls plus three standard deviations (mean+3SD). Statistical
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analysis was carried out in SPSS software, version 24.0. Differences were considered statistically
significant by significant level 0.01 or 0.05.
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Chapter 3: Results
3.1

Screening of patients’ sera with OS, OC and normal individuals for the presence of
autoantibodies to potential TAAs.
In this initial study, we have tested 52 sera from OS patients (age 4-64 years), 28 sera from

OC patients (age 4-52 years) and 49 age-sex matched normal human individuals, for the presence
of autoantibodies to the TAAs from extracted protein antigens from U2-OS and Saos-2 culture
cells in 1-D Western blot and by indirect immunofluorescence (IIF). We found that some of the
patients’ sera contained autoantibodies reacting with one or more cellular antigens (Fig. 4&6). As
shown in Table 5, autoantibodies were detected in up to 96.2% sera from patients with OS, which
were significantly higher than that in normal human sera (30.6% and 32.7%). In contrast, there is
no significate association between OC and NHS group, which implies that the OS sera may
encompass more specific autoantibodies than OC sera against the proteins extracted from either
U2-OS or Saos-2 cell lines. Western blotting analysis of five representative sera from each of the
cohort groups against these two cell extracted proteins are shown in Fig. 4&6. Interestingly, 38.5%
(20/52), 30.8% (16/52), 28.8% (15/52), 26.9% (14/52), 15.4% (8/52), 13.5% (7/52), 13.5% (7/52),
11.5% (6/52) OS sera were identified by 1-D Western blotting analysis containing antibodies
against unknown cellular protein antigens from U2-OS cell extracted proteins around 47KD,
33KD, 60KD, 54KD, 37KD, 27KD, 17KD and 29KD respectively. As shown in Fig. 5, no
reactivity with the 60KD, 37KD, 27KD, 17KD and 29KD proteins were detected in 49 normal
human sera. For the 1-D Western blotting analysis with Saos-2 cellular protein, 48.1% (25/52),
36.5% (19/52), 30.8% (16/52), 28.8% (15/52), 26.9% (14/52), 21.2% (11/52), 17.3% (9/52), 15.4%
(8/52), 11.5% (6/52), 11.5% (6/52) OS sera were identified containing antibodies against unknown
cellular protein antigens around 47KD, 37KD, 66KD, 56KD, 33KD, 60KD, 29KD, 27KD, 17KD
and 50KD respectively. Additionally, no reactivity with the 37KD, 66KD, 33KD, 29KD and 17KD
proteins were found in 49 normal human sera (Fig. 7). Seven identified protein bands (47KD,
33KD, 60KD, 37KD, 27KD, 17KD, 29KD) were overlapped between these two cell lines.
Moreover, further analysis of the autoantibody positivity to 27 KD and 50KD Saos-2 cellular
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antigens in OS showed no significant difference with NHS. The most common immunoreactivity
band is around the 47 KD region (38.5% and 48.1% in U2-OS and Saos-2 cell proteins), which
implies that the targeting TAAs could be focused on the protein with molecular weight around
47KD.

Table 5: Frequency of autoantibodies in sera from patients with OS, OC and normal
human responses to the antigens extracted from U2-OS and Saos-2 cell lines in Western
blotting

No.
tested

Frequency of autoantibodies
against cellular protein
antigens from U2-OS cell

Frequency of autoantibodies
against antigens cellular
protein from Saos-2 cell

Osteosarcoma

52

94.2% (49/52)*

96.2% (50/52)*

Osteochondroma

28

50.0% (14/28)

64.3% (18/28)

Normal human

49

30.6% (15/49)

32.7% (16/49)

Serum samples

*P value relative to NHS: P< 0.001.
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Figure 4: Detection of autoantibodies against cellular protein antigens extracted from U2OS cell line in sera from patients with OS, OC and NHS. 1-D Western blotting shows that
autoantibodies against the protein antigens extracted from U2-OS cell line detected after probing
with sera OS# 16, 19, 21, 25, 26 (Lanes 1-5) were significantly higher than that in sera OC# 24,
25, 26, 27, 28 (Lanes 6-10) and normal human sera N# 28, 29, 30, 31, 32 (Lances 11-15). OS:
Osteosarcoma; OC: Osteochondroma; NHS: Normal Human Sera.
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Figure 5: Frequency of autoantibodies against the 47KD, 33KD, 60KD, 54KD, 37KD, 27KD,
17KD and 29KD autoantigens from U2-OS cell line in sera from patients with OS, OC and
NHS.
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Figure 6: Detection of autoantibodies against cellular protein antigens extracted from Saos2 cell line in sera from patients with OS, OC and NHS. 1-D Western blotting shows that
autoantibodies against the protein antigens extracted from Saos-2 cell line detected in sera from
patients with OS# 16, 19, 21, 25, 26 (Lanes 1-5) were significantly higher than that in sera OC#
24, 25, 26, 27, 28 (Lanes 6-10) and normal human sera N# 1, 2, 3, 4, 5 (Lances 11-15). OS:
Osteosarcoma; OC: Osteochondroma; NHS: Normal Human Sera.
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Figure 7: Frequency of autoantibodies against the 47KD, 37KD, 66KD, 56KD, 33KD, 60KD,
29KD, 27KD, 17KD and 50KD autoantigens from Saos-2 cell line in sera from patients with
OS, OC and NHS.

3.2

Indirect immunofluorescence (IIF) microscopy
Reactivity with cancer cells for all selected serum samples with strong immunoreactivity

including those reacting with the top four common proteins band around 33KD, 47KD, 54KD and
60KD from U2-OS 1-D Western blotting analysis were further confirmed by indirect
immunofluorescence (IIF) assay with commercially purchased HEp-2 antinuclear antigen tissue
slides. Subcellular fractionations of HEp-2 cells were incubated with representative antigen
(47KD, 54KD and 60KD protein antigens) enriched OS sera showing predominant cytoplasmic
staining patterns with more intense staining in the perinuclear regions, whereas, the 33KD protein
antigens shows nucleoplasm granular immunofluorescence staining pattern (Fig. 8).
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Figure 8: Representative immunofluorescence staining pattern of anti-33KD, 47KD, 54KD
and 60KD autoantibodies positive in the OS serum. A, Sjogren's Syndrome A Control (SS-A)
human sera which showed a nucleoplasm granular immunofluorescence staining pattern was used
as positive control; B, PBS was used as blank control; C&D, two representative anti-60 KD
autoantibody positive OS sera; E&F, two representative anti-54 KD autoantibody positive OS sera;
G&H, two representative anti-47 KD autoantibody positive OS sera; I&J, two representative anti33 KD autoantibody positive OS sera.

3.3

Identification of candidate TAAs by SERPA approach
In the present study, the SERPA approach was applied to identify the repertoire of

immunereactive potential TAAs as biomarkers in OS. Combined with advances in genomics and
mass spectrometry, the SERPA approach has allowed the facile identification of immunoreactive
proteins. A brief description of this approach is shown in Fig. 3. In order to obtain a global view
of the proteins in U2-OS and Saos-2 cell lines, proteins extracted from US-OS and Saos-2 cells
were analyzed by 2DE-PAGE using the broad-range pH 3-10 non-linear gradient gel strips for the
isoelectricfocusing (IEF) strip. This broad range pH can provide the possibility for a view of most
of the constituent proteins contained in cells and allow for the separation of protein with pI from3
to 10. After electrophoresis, the gels were either stained with Coomassie blue or transferred onto
nitrocellulose membrane. As shown in Fig. 9&10, a 15% SDS-PAGE was used in the second
dimension gel to separate proteins with molecular weight from 10-250 KD. Subsequently, proteins
were transferred to nitrocellulose membrane and probed with primary sera and conjugated
secondary antibody, as per traditional Western blotting. We selected 11 representative sera from
OS patients without any treatment and with common strong immunoreactivity in the 1-D Western
blotting. The nitrocellulose membranes were incubated with these 11 representative OS sera and
a pool of 5 NHS used as control. Images of immunoblots of 2-DE analysis gels exposed on films
were overlaid and digitally matched with images of the corresponding Coomassie Blue-stained
reference 2-DE gels (Fig. 11&12). Excising the identified immunoreactive proteins from a second
protein stained 2DE-PAGE, and subsequent digestion with trypsin allows identification of proteins
using mass spectrometry based techniques. Protein spots in stained 2D gels corresponding to the
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immunoreactive spots were then processed for MALDI-TOF/TOF MS analysis and the resulting
MS/MS spectra were analyzed by the MASCOT search engine using the NCBI and UniProt
database. The filtering process for top scores of protein hits in the excised immunoreactive spots
was based on molecular weight, isoelectric point, percent coverage, number of unique peptides,
and total number of proteins identified for each spot.
Of interest, alpha-enolase (ENO1) was identified as the top hit from the 47 KD spot
recognized by 10 of the 11 selected OS sera and without immunoreaction with NHS pool (Table
7). SERPA analysis of other immunoreactive spots with other region recognized by these 11
reactive OS sera revealed additional candidate TAAs involved in different molecule functions
(Table 6). As shown in Table 6, a total of 20 proteins from U2-OS and Saos-2 cell lines hits were
identified from the analysis of 2-DE spots recognized by these 11 highly reactive OS sera
compared with the NHS pool. Moreover, five of them (ENO1, GAPDH, TPI1, DENND4A,
TUBA1C) were identified successfully from both of two cell lines (Fig.13). Of 20 identified
proteins, the molecular and cellular functions of all proteins have been documented in literatures,
and several proteins were reported relating to cancer in previous studies (Table 6). The
representative peptide mass finger printing (PMF) and MS/MS spectra of two ENO1 peptides from
the excised 47 KD spot from Saos-2 and U2-OS cell lines were shown in Fig.14. The other PMF
detailed information was listed in supplemental file.
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Figure 9: Total proteins from U2-OS cell analyzed by 2DE-gel. The U2-OS cell sample was
lysed in IEF buffer and run on a pH3–10 Bio-Rad IPG IEF system. The second dimensional run
was performed on 15 % gradient SDS-PAGE gels and the gels were subsequently processed with
Coomassie blue staining.

Figure 10: Total proteins from Saos-2 cell analyzed by 2DE-gel. The Saos-2 cell sample was
lysed in IEF buffer and run on a pH3–10 Bio-Rad IPG IEF system. The second dimensional run
was performed on 15 % gradient SDS-PAGE gels and the gels were subsequently processed with
Coomassie blue staining.
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Figure 11: 2-DE Western blotting analysis of U2-OS cells was probed with one representative
OS serum sample (# 26) and a pool of five 5 NHS (# 3, 8, 7, 1, 36) used as control. A, The 2DE protein profile of U2-OS cells (left panel). Western blotting analysis of 2-DE gel was probed
with one representative osteosarcoma serum sample OS (# 26) which contains antibodies to the
47KD protein (middle panel). The nitrocellulose membrane transferred from 2-DE gel was stained
with Ponceasu S (right panel). B, The 2-DE protein profile of U2-OS cells (left panel). Western
blotting analysis of 2-DE gel was probed with a pool of five 5 NHS (# 3, 8, 7, 1, 36) (middle
panel). The nitrocellulose membrane transferred from 2D gel was stained with Ponceasu S (right
panel).
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Figure 12: 2-DE Western blotting analysis of Saos-2 cells was probed with one representative
OS serum sample (# 11) and a pool of five 5 NHS (# 3, 8, 7, 1, 36) used as control. A, The 2DE protein profile of Saos-2 cells (left panel). Western blotting analysis of 2-DE gel was probed
with one representative osteosarcoma serum sample OS (# 11) which contains antibodies to the
47KD protein (middle panel). The nitrocellulose membrane transferred from 2-DE gel was stained
with Ponceasu S (right panel). B, The 2-DE protein profile of Saos-2 cells (left panel). Western
blot analysis of 2-DE gel was probed with a pool of five 5 NHS (# 3, 8, 7, 1, 36) (middle panel).
The nitrocellulose membrane transferred from 2D gel was stained with Ponceasu S (right panel).
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Table 6: Top candidate OS autoantigens identified from autoantibodies profiling of multiple human OS sera
Accession No.

Candidate TAAs

Acronym

NP_001419.1

Alpha-enolase

ENO1

Average # Unique
Peptides
20

U1

3B97_C

Alpha-enolase

ENO1

16

284

2

S4

NP_066272.1

PDZ and LIM domain protein 1

PDLIM1

18

155

Metal-binding, Zinc

3

S5

CAA37794.1

Uracil-DNA glycosylase

UNG

12

93

Hydrolase

4

S6

CAA25833.1

Glyceraldehyde-3-phosphate dehydrogenase

GAPDH

13

115

Oxidoreductase, Transferase

U4

NP_001243728.1

Glyceraldehyde-3-phosphate dehydrogenase

GAPDH

13

86

S8

4BR1_A

Triosephosphate isomerase

TPI1

18

328

U6

AAH17917.1

Triosephosphate isomerase

TPI1

15

117

6

S9

1PE0_A

Protein/nucleic acid deglycase DJ-1

PARK7

14

147

Chaperone, Hydrolase, Protease, RNA-binding

7

S11

ADK47995.1

C-myc promoter-binding protein

DENND4A

12

182

DNA-binding, Guanine-nucleotide releasing factor

U7

ADK47995.1

C-myc promoter-binding protein

DENND4A

11

102

8

S16

4PJ1_M

60 kDa heat shock protein, mitochondrial

HSPD1

20

128

Chaperone, Hydrolase

9

S17

NP_001814.2

Creatine kinase B-type

CKB

14

102

Kinase, Transferase

10

S19

5JLH_D

Actin, cytoplasmic 1

ACTB

17

437

Cell motility

11

S20

NP_001830.1

CNN3

13

77

Actin-binding, Calmodulin-binding

12

S21

NP_004172.2

UCHL1

10

198

Hydrolase, Ligase, Protease, Thiol protease

13

S23

NP_116093.1

Calponin-3
Ubiquitin carboxyl-terminal hydrolase
isozyme L1
Tubulin alpha-1C chain

TUBA1C

18

169

GTP-binding, Nucleotide-binding

U12

NP_116093.1

Tubulin alpha-1C chain

TUBA1C

14

142

14

S24

NP_005733.1

Protein disulfide-isomerase A6

PDIA6

11

78

Chaperone, Isomerase

15

S24

ACA06103.1

Vimentin

VIM

27

192

Host-virus interaction

16

S29

3POS_C

Calreticulin

CALR

13

128

Chaperone

17

U13

NP_821133.1

Tubulin beta chain

TUBB

23

358

GTP-binding, Nucleotide-binding

18

U14

AAH16768.1

Nucleophosmin

NPM1

11

319

Chaperone, RNA-binding

19

U22

AAA62175.1

Heat shock protein beta-1

HSPB1

13

372

Chaperone

20

U25

NP_981946.1

Stathmin

STMN1

15

484

Developmental protein

No.
1

5

No. in
gel
S1
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Score

Molecular function

311

DNA-binding, Lyase, Repressor

Isomerase

Table 7: The appearance of identified proteins in 11 sera from patients with OS
Identified proteins
Alpha-enolase

No. in gel
S1&U1

OS Sera No.
6

9

10 11 14 19 20 24 26 27 33

X X

X

X

PDZ and LIM domain protein 1

S4

Uracil-DNA glycosylase

S5

X

X

X

Glyceraldehyde-3-phosphate
dehydrogenase

S6& U4

X

X

X

Triosephosphate isomerase

S8&U6

Protein/nucleic acid deglycase
DJ-1

X

X

X

X

X

X

X

X

X

X
X

X

X

X

X

S9

X

C-myc promoter-binding
protein

S11&U7

60 KD heat shock protein,
mitochondrial

S16

Creatine kinase B-type

S17

Actin, cytoplasmic 1

S19

X

X

Calponin-3

S20

X

X

Ubiquitin carboxyl-terminal
hydrolase isozyme L1

S21

X

Tubulin alpha-1C chain

X

X X

X

X

X
X

X

X

X

X
X

X

Vimentin

S24

X

Calreticulin

S29

X

Tubulin beta chain

U13

Nucleophosmin

U14

Heat shock protein beta-1

U22

Stathmin

U25

X

X

X
X

S24

X

X

S23&U12

Protein disulfide-isomerase A6

X

X
X

X
X

X

X
X

X

X
X

X

X
X
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Figure 13: Comparison between proteins identified from U2-OS and Saos-2 cell lines. Five
identified proteins (ENO1, GAPDH, TPI1, DENND4A, and TUBA1C) were overlapped between
these two cell lines.
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Figure 14: Peptide mass finger printing (PMF) and MS/MS spectra of representative ENO1
peptides identified from excised 2-DE gel protein spots from Saos-2 and U2-OS cell lines. A,
PMF of Spot # 1 from 2-DE gel of Saos-2 cell line. B, MS/MS spectra of Spot # 1 from 2-DE gel
of Saos-2 cell line. C, PMF of Spot # 1 from 2-DE gel of U2-OS cell line. B. MS/MS spectra of
Spot # 1 from 2-DE gel of U2-OS cell line.

3.4

Functional categorization of identified proteins
Gene ontology (GO) annotation was performed to better understanding the biological

functions of these differentially expressed proteins. The 20 identified proteins were categorized
into three groups including molecular function, biological process, and cellular component.
Proteins in each group were further categorized in different sub-groups. The results of GO
annotation are presented Fig. 15. These differentially expressed proteins were predicted to be
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involved in 48 different biological processes, to possibly have 10 kinds of molecular functions,
and to involve 8 categories of cellular components.

Figure 15: Functional categorization of twenty identified proteins. Twenty identified proteins
were functionally categorized in three groups based on gene ontology (GO) annotation terms and
searching sequences against the databases. Three functional groups include molecular function,
biological process and cellular component. Proteins in each group were further categorized in
different sub-groups.

3.5

Prevalence of autoantibody to ENO1 in OS, OC and normal individuals
After identifying that several sera in our initial OS patient test cohort contained

autoantibodies to ENO1, we evaluated anti-ENO1 autoantibody levels in sera from patients with
OS and controls, using the full-length recombinant ENO1 protein as coating antigen in
ELISA97,99,100, to determine the frequency of these autoantibodies in a validation cohort of OS sera
(n=95), as well as a non-OS control cohort of OC (n=28) and NHS (n=49). The ROC curves
discriminated between OS and OC from NHS groups of anti-ENO1 autoantibody with AUCs of
0.853, P<0.001 (OS vs NHS) and 0.758, P<0.001 (OC vs NHS), respectively (Fig. 16). As shown
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in Fig. 17, sera from OS patients showed a significantly higher frequency (12/52, 23.1%) and
levels of autoantibodies to ENO1 compared to OC sera (1/28, 3.6%, P<0.05) and NHS (1/49, 2.0%,
P<0.01), suggesting that they are OS-related. Western blotting analysis with representative
positive sera against purified ENO1 showed that all of the 12 sera have reaction against purified
ENO1 with different signal density. Nine of twelve sera reacted strongly against purified ENO1,
but 3 weakly against purified ENO1 in Western blotting. By contrast, both of 10 randomly selected
OC and NHS sera shows no immmoreactivity or very weak reaction signal against purified ENO1
by Western blotting (Fig. 18).

Figure 16: The ROC curves discriminate OS from OC and NHS groups of anti-ENO1
autoantibody. Receiver operating characteristic (ROC) curve analysis of ENO1 expression to
discriminate the OS group from the OC and NHS groups. The area under the ROC curve (AUC)
corresponding to the comparisons between pairs of these groups is indicated.
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Figure 17: Frequency of serum anti-ENO1 autoantibody in sera from patients with OS,
OC and normal human sera. A, ELISA scatter dot plot shows OD values with solid lines
representing the mean of each cohort, OS, OC and NHS. The dotted line represent the mean value
of the normal individuals’ cohort plus three standard deviations to determine levels and frequency
of autoantibody reactivity against ENO1. B, The graph shows higher frequency of anti-ENO1
antibodies in OS patient sera compared to OC and NHS sera.

Figure 18:
Western blotting analysis with representative positive sera in ELISA.
Representative sera from patients with OS (lanes 1-3), OC patients (lanes 4-6) and normal human
sera (lanes 7-9) probed against purified ENO1 showed differences in immunoreactivity by Western
blotting. 9 of 12 (75.0%) sera with positive OD values were consistently positive in Western
blotting.

3.6

Evaluation of anti-ENO1 autoantibody level in OS patients along the disease
progression.
Since 67 serial serum samples from 24 OS patients were obtained at a wide range of time

period (ranging 0 to 400 days after diagnosis), we questioned whether anti-ENO1 autoantibody
levels might change along the disease progression. As shown in Fig. 19A, the presence of
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autoantibodies to ENO1 was assessed by ELISA over time in the serially collected at three time
points: diagnosis, before surgery and after surgery. The OD value of before and after surgery were
the average OD determined on serum that had been collected at a particular time point after surgery
during a month period (mean, 4.15 months). Unexpectedly, although there is no signification
association of anti-ENO1 autoantibody titers at these three time points (Fig. 19A), descant of
ENO1 immunoreactivity was observed in most patients along the disease progression (Fig.
19B&C&D), which may imply a potential association between changes in anti-ENO1
autoantibody titers and disease progression.
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Figure 19: Serial assay of anti-ENO1 autoantibody by ELISA in 24 patients with OS along
the disease progression. A, The OD values of anti-ENO1 autoantibody over time in the serially
collected at three time points: diagnosis, before surgery and after surgery. B&C&D, Serial study
of anti-ENO1 antibody levels (OD value) during a 1-year period in three representative OC
patients.

3.7

Expression of ENO1 in OS tissues by immunohistochemistry with tissue microarray
To explore the possibility that ENO1 is overexpressed in OS, an expression analysis of this

protein in OS tissue was performed by immunohistochemistry. Tissue microarray slides includes
51 cases of osteosarcoma (1 case was lost during performance of immunohistochemistry), 27
chondrosarcoma (4 cases was lost during performance of immunohistochemistry), plus 2 bone
marrow tissue, and single core per case. And normal bone tissue microarray contains 11 cases of
bone tissue, 1 osteosarcoma, and duplicate cores per case. As shown in Table 8, the results
indicated that there was significant difference of the frequency of ENO1 overexpression in both
osteosarcoma and chondrosarcoma tissues with 100% positive rate compared with normal bone
tissue with 0% positive rate. However, the ability in distinguishing osteosarcoma from
chondrosarcoma individuals was not found to have statistical significance. To investigate the
possible relationship between theses histological characteristics and ENO1 expression, we
analyzed the histological characteristics of 50 osteosarcoma specimens from the same tissue array
that had information on TNM, pathology grade, and clinical stage. Eventually, there is no
statistically significant difference between these groups. Fig. 20 shows representative normal with
negative immunostaining for ENO1, osteosarcoma and chondrosarcoma tissues with positive
immunostaining for ENO1.
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Table 8: Expression profile of ENO1 in Osteosarcoma, Chondrosarcoma and normal bone
tissue microarray
Osteosarcoma
n=50

Chondrosarcoma
n=23

Normal
n=22

Age
Mean, SD
Range
Gender (%)
Male
Female
TNM (%)
T1N0M0
T2N0M0
Grade (%)
Grade1-2
Grade 3-4
Stage (%)
<IIA
>IIB
ENO1 Expression (%)
PR+SI≥4
PR+SI<4

24.7, 13.7
7-69

37.8, 16.1
12-74

61.6, 11.0
41-84

30 (60.0)
20 (40.0)

15 (65.2)
8 (34.8)

20 (90.9)
2 (9.1)

23 (100)
0 (0)

0 (0)
22 (100)

7 (14.0)
43 (86.0)
6 (12.0)
44 (88.0)
9 (18.0)
41 (82.0)
50 (100)
0 (0)
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Figure 20: Evaluation of ENO1 protein expression in normal, osteosarcoma and
chondrosarcoma tissues by immunohistochemistry. A&B, Negative staining of ENO1
expression in representative normal bone tissue at 100X and 400X magnification respectively;
C&D, Positive staining of ENO1 expression in osteosarcoma tissue at 100X and 400X
magnification respectively; E&F, Positive staining of ENO1 expression in chondrosarcoma tissue
at 100X and 400X magnification respectively.

54

3.8

Autoantibodies levels to other 6-TAAs identified from SERPA in OS patients and
control individuals
Six TAAs (NPM1, GAPDH, TPI1, HSP60, PDLIM1, STMN1) were selected from the 20

identified based on the findings of 1-D Western blotting and SERPA. Furthermore, they were
considered to be oncogenes, tumor suppressor genes, growth factors, or cell cycle-related proteins.
Many previous studies have demonstrated these serum antibodies to be autoimmunogenic, and
detectable in serum from various cancer studies3,97,100,113-115. We continuously evaluated autoantibodies against 6 TAAs using individual sera from 95 patients with OS, 28 sera from OC as
well as 49 NHS. All of these 6 TAAs exhibited statistically significant increased autoantibody
responses in patients with OS compared to NHS, while no differences were observed for the
autoantibodies in OC and NHS groups (Fig. 21). However, the frequency of autoantibodies
positive reactivity in OS sera against 4 of 6 TAAs (NPM1, GAPDH, PDLIM1, STMN1) was
observed to be significant higher than that in OC group.
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Figure 21: Frequency of serum anti-NPM1, anti-GAPDH, anti-TPI1, anti-HSP60, antiPDLIM1, anti-STMN1 autoantibodies in sera from patients with OS, OC and normal
human sera. ELISA scatter dot plot shows OD values of anti-6 TAAs respectively with solid
line represents the mean of each cohort, OS, OC and NHS (Left Panel). The dotted line
represents the mean value of the normal individuals’ cohort plus three standard deviations to
determine levels and frequency of autoantibody reactivity against these 6 TAAs. B, The graph
shows higher frequency of anti-6 TAAs antibodies in OS patient sera compared to OC and NHS
sera.
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3.9

Design of TAA arrays for specific OS detection.
Our previous studies indicate that the combination of antibodies to multiple TAAs yield

higher sensitivity for diagnosis of liver cancer103, prostate cancer116, lung cancer117. Since the OSrelated TAAs has been identified and validated, we further refined a miniarray to combine ENO1
with other 6 TAAs (NPM1, GAPDH, TPI1, HSP60, PDLIM1, STMN1) to enhance autoantibody
detection and explore their utility in OS detection and diagnosis. Positive reactivity for 7-TAAs
array was again defined as having an OD value above three standard deviations plus the mean OD
in the 49 matched NHS. The frequencies of positive reactions for 7-TAAs array in OS, OC and
NHS patients are shown in Fig. 22A. The 7-TAAs array showed that 90.4% of all OS patients were
found to have levels above the OD cutoff value in one or more of these seven TAAs compared to
14.3% in the NHS (P<0.01) (Table 9). We generated a multiple-variable ROC curve by using the
predictive probability variables of the 7-TAAs array. The analysis showed an AUC of 0.938 (95%
CI: 0.886-0.990, P=0.000) within OS vs NHS (Fig. 22B) and an AUC of 0.911 (95% CI: 0.8440.978, P=0.000) within OS vs OC (Fig. 22C).
Table 9: Evaluation of 7-TAAs array in the diagnosis of OS.

7-TAAs
Any +
All Total

OS
47
5
52

NHS
7
42
49

Sensitivity=47/52=90.4%
Specificity=42/49=85.7%
False positive rate=7/49=14.3%
False negative rate=5/52=9.6%
Positive predictive value=47/54=87.3%
Negative predictive value=42/47=89.4%
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Total
54
47
101

Figure 22: Frequency of autoantibodies against 7-TAAs (ENO1, NPM1, GAPDH, TPI1,
HSP60, PDLIM1, STMN1) in sera from patients with OS, OC and normal human sera. A,
The graph shows higher frequency of anti-7 TAAs autoantibodies in OS patient sera compared to
OC and NHS sera; B, ROC curve of OS (n=52) vs NHS (n=49) for the panel of seven TAAs
combination; C, ROC curve of OS (n=52) vs OC (n=28) for the panel of seven TAAs combination.
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Chapter 4: Discussion
4.1

Screening of patients’ sera with OS, OC and normal individuals for the presence of
autoantibodies to potential TAAs.
Autoimmune phenomena manifested as autoantibodies to cellular components have been

described in many types of cancers. The objective of this study was to identify and characterize
the autoantibodies and targeted antigens as biomarkers in OS, and further analyze the frequency
and specificity of autoantibodies in sera from patients with OS. To screen the autoantibodypositive sera, we initially have tested 52 sera from OS patients, 28 sera from OC patients and 49
age-sex matched normal human sera, for the presence of autoantibodies to the TAAs from
extracted protein antigens from U2-OS and Saos-2 culture cells in 1-D Western blotting and by
indirect immunofluorescence (IIF).
Our observation that sera from OS patients showed a stronger immunoreactivity against
both U2-OS and Saos-2 (94.2% and 96.2%) cellular proteins by 1-D Western blotting than sera
from OC (50.0% and 64.3%) and NHS (30.6% and 32.7%) under identical experimental
conditions, which is consistent with the proposed notion of this project that OS may exhibit
different molecular phenotypes that could influence differential anti-tumor immune responses.
Seven identified protein bands (47KD, 33KD, 60KD, 37KD, 27KD, 17KD, 29KD) were observed
from both of these two cell lines. Moreover, further analysis of the autoantibody positivity to 27KD
and 50KD Saos-2 cellular antigens in OS shows no significant difference with NHS. Intriguingly,
among 52 sera from patients with OS, 38.5% (20/52) and 48.1% (25/52) of sera contained
autoantibody against a protein migrating around 47KD region on SDS-PAGE gel of U2-OS and
Saos-2 cellular proteins respectively. We may narrow the focus on the identified protein with
molecular weight around 47KD.
HEp-2 cells have been shown to have greater sensitivity than tissue sections and yield
sharper pattern recognition118, which is still considered the gold standard for screening of
autoantibodies119. Reactivity with cancer cells for all selected serum samples with strong
immunoreactivity including those reacting with the top four common proteins band around 33KD,
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47KD, 54KD and 60KD from U2-OS 1-D Western blotting analysis were further confirmed by
using IIF on HEp-2 antinuclear antigen tissue slides. Subcellular fractionations of Hep-2 cells were
incubated with representative antigen (47KD, 54KD and 60KD protein antigens) enriched OS sera
showing predominant cytoplasmic staining patterns with more intense staining in the perinuclear
regions, whereas, the 33KD protein antigens showed nucleoplasm granular immunofluorescence
staining pattern. Moreover, the same antigens enriched OS sera showed the similar staining
pattern, which confirmed the results of immunoreactivity with 1-D Western blotting. Particularly,
subcellular fractionation of HEp2 cells showed the unknown 47KD proteins were predominantly
in the cytoplasm, and were not found in the nuclear fraction, which is consistent with monoclonal
ENO1 antibody staining in these cells in our previous studies100, in U2-OS as well as MCF7 in
other studies indicating mainly localization to plasma membrane & cytosol and in addition
localized to the nucleoplasm (Fig. 23)104.

Figure 23: Immunofluorescent staining of human cell line U2-OS and MCF7 against ENO1.
A, Immunofluorescent staining of human cell line U2-OS shows localization to nucleus, plasma
membrane & cytosol. Antibody dilution: 1:66; B, Immunofluorescent staining of human cell line
MCF7 shows localization to nucleoplasm, plasma membrane & cytosol. Antibody dilution 1:200.
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4.2

Identify and characterize novel TAAs in OS using serological proteome analysis
(SERPA) approach.
The rationale behind the SERPA approach is that intracellular proteins involved in

carcinogenesis provoke autoantibody responses, and therefore autoantibodies can be used as
probes to isolate, identify, and characterize potential oncoproteins. The SERPA approach has been
recently widely implemented for identifying TAAs in cancer patients94,95,100. While SEREX
methodology has been used for over several decades, serval limitations make it far from
satisfactory to identified TAAs as potential markers in cancer. For instance, construction of cDNA
expression library is essential for serological screening, however, this procedure is complex and
time-consuming. Compared to SEREX, the SERPA allows individual screening of a large number
of sera, as well as identification of a large number of candidate TAAs in a shorter time period. The
proteome-based approach, which is generally named as immunoproteomics115, can also distinguish
between antigen isoforms and detect the presence of autoantibodies directed against posttranslational modifications of specific targets. Constantly evolving advances in SEPRA offer great
promise in the understanding of the molecular basis of cancer120. This shed light on rapid advances
in determining protein antigens for vaccine development121, immune correlates, and biomarkers
for disease diagnosis and prognosis115. The need to reliably identify and validate protein biomarker
expression and improve disease diagnosis is underscored by the increased survival of bone cancer
patients who are diagnosed early122.
A SERPA approach was implemented in this project for the identification of TAAs that
induce antibody responses in OS. The two-dimensional gel electrophoresis system (2-DE) has been
set up, and the proteome-based technique has been used in our lab in some other project for
identification of TAAs in hepatocellular carcinoma94, esophageal squamous cell carcinoma95,
prostate cancer96,97, lung cancer98,99 and liver fibrosis100. Although though the SERPA approaches
for cancer biomarkers has revealed many possible candidates, none have demonstrated a screening
of sera from patients with OS and OC, particularly enough promise to be implemented clinically.
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We selected 11 representative OS sera with common strong immunoreactivity from the
results of 1-D Western blotting and a pool of 5 NHS used as control to examine them by SERPA.
The immunoseroproteomics profiling led to the identification of 20 potential TAAs of 56 protein
spots targeted by serum autoantibodies in OS patients compared with the NHS pool. Especially,
alpha-enolase (ENO1) (11 of 12) had a higher immunoreactive frequencies in sera with OS.
Moreover, five of them (ENO1, GAPDH, TPI1, DENND4A, TUBA1C) were identified
successfully from both of two cell lines. Of 20 identified proteins, the molecular and cellular
functions of all proteins have been documented in literatures, and several proteins were reported
relating to cancer in previous studies.
Then we performed Gene ontology (GO) annotation study to better understanding the
biological functions of these differentially expressed proteins. The 20 identified proteins were
categorized in three groups including molecular function, biological process, physiological and
cellular component. These differentially expressed proteins were predicted to be involved in 48
different biological processes, to possibly have 10 kinds of molecular functions, and to involve 8
categories of cellular components. For instance, in addition to ENO1, the protein hits included key
chaperone such as Protein/nucleic acid deglycase DJ-1 (PARK7), 60 KD heat shock protein
(HSPD1), Protein disulfide-isomerase A6 (PDIA6), Calreticulin (CALR), Nucleophosmin
(NPM1), Heat shock protein beta-1 (HSPB1), Additional candidate TAAs identified by our
SERPA approach have been associated with Metal-binding, Hydrolase, Transferase, Isomerase,
DNA-binding, cell motility, GTP-binding and so on.
Cytoplasmic enzyme may also function in altering the tumor microenvironment123,124. For
example, a number of studies have demonstrated that glycolytic enzymes can relocate from the
mitochondria to the plasma membrane during cytoskeletal remodeling, leading to influence on cell
motility, extracellular matrix degradation, and plasminogen signaling125-127. ENO1 and GAPDH
have been revealed to be “moonlight” as plasminogen receptors, contributing to the conversion of
plasminogen to plasmin and promoting extracellular matrix remodeling with ensuing increased
cancer cell migration and metastasis125,126,128. In glioma tumors, ENO1 is overexpressed to
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promote migration and tissue invasion129, while its secretion from prostate cancer stromal cells
was also found to improve cell migration130. One group illustrated that a small molecular inhibitor
of ENO1 reduced pancreatic cancer cell invasion and migration properties131, suggesting that this
cytoplasmic enzyme plays a significant role in aggressive disease progression. The overexpression
of these metabolic enzymes on the surface of tumors could break immune tolerance, making them
targets of humoral responses. Of interest, anti-ENO1 autoantibodies may also assuage tumor
metastasis by interfering with plasminogen binding, thus resulting in reduced tumor growth,
migration and invasion132. This makes ENO1 and other cytoplasmic enzymes likely a contributor
to plasminogen binding attractive candidates for anti-cancer immunotherapy.
4.3

Validate the potential value of newly identified TAA- Alpha-enolase (ENO1) as OS
biomarkers.
As a potential TAA to be considered as a useful serological biomarker for cancer diagnosis

or prognosis, it has to be preferentially recognized by sera from patients with the particular tumor
type in which the antigen was identified, when compared to sera from normal controls, other bone
tumors, or other diseases. Once a TAA is identified, the combined use of various immunoassays
is required to enhance detection of the autoantibodies and determine more accurately the frequency
of these autoantibodies in patient sera. The reason for this aim is that there is often an incomplete
correlation in the detection of autoantibodies to TAAs between different immunoassays59,
probably due to differences in the sensitivity of the various assays or changes in antigen
conformation from one assay platform to another. Therefore, it is essential to establish that the
candidate TAA is indeed expressed in OS, and to correlate the presence of an anti-TAA
autoantibody with TAA expression in autologous bone tumor tissue.
Perhaps the greatest challenge in the investigation of serological study in OS is the serum
samples collection, due to its low incidence rate all around the world. In addition, it is less evident
that the incidence of the disease has an uneven geographic distribution worldwide. We fortunately
collected 95 serum samples from 52 OS patients including 24 patients with serial serum samples
obtained at the time of diagnosis or at different time points along the disease progression since
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2014 from one of the largest orthopedic specialty hospitals in the world- Henan Luoyang
Orthopedic-Traumatological Hospital (HLOH) in China. Based on our extensive experience in
characterizing autoantibody responses in cancer, we determined the frequency of autoantibodies
to the identified potential TAAs in patients with different clinical stages of OS, benign bone tumor,
as well as in age and sex matched normal individuals without any no cancer diagnosis. We chose
28 age-matched OC sear as a benign control because it is the most common benign bone tumor
and these samples were readily available in our study. The 49 normal human sear used as control
group includes both young and older patients, corresponding to the two age-specific peaks in
frequency in OS. This analysis is essential to establish the sensitivity, specificity, and positive
predictive value of individual antibody-antigen system as biomarkers of OS.
After demonstrating that most of sera in our initial 11 patients’ test of SERPA contained
autoantibodies to ENO1, we subsequently set up a validation by ELISA, using purified ENO1 as
target TAA to determine the frequency of these autoantibodies in an expanded validation cohort
of OS patients (n=95), as well as OC patients (n=28) and NHS (n=49). These cohorts contained
all of the sera tested in our initial screening plus additional sera acquired at different time points
along with the disease progression. The results of ROC curves analysis of anti-ENO1 autoantibody
indicated it predominately discriminate the OS group from OC and NHS groups with AUCs of
0.853, P<0.001 (OS vs NHS) and 0.758, P<0.001 (OS vs OC). Furthermore, the ROC curves
analysis also showed that anti-ENO1 can differentiate OC patients from normal individuals with
AUC (95%CI) of 0.711 (P<0.001). Sera from OS patients showed a significantly higher frequency
(12/52, 23.1%) and levels of autoantibodies to ENO1 compared to OC sera (1/28, 3.6%, P<0.05)
and NHS (1/49, 2.0%, P<0.01), suggesting that they are OS-related.
Given these intriguing results, we then explored whether theses selected positive sera that
recognized ENO1 in cellular cells by 1-D WB would also recognize purified ENO1 by Western
blotting, and whether the positive sera that reacted against ENO1 by ELISA would also recognize
purified ENO1 by Western blotting. We then perform Western blotting with the selected 12 sera
which have positive reaction with ENO1 in both 1-D WB and ELISA against purified ENO1.
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Interestingly, all of the 12 sera have reaction against purified ENO1 with different signal density.
Nine of twelve sera reacted strongly against purified ENO1, but 3 weakly against purified ENO1,
which indicates 75.0% sera with positive OD values are consistently positive in Western blotting.
By contrast, both of 10 randomly selected OC and NHS sera shows no immunoreactivity or very
weak reaction signal against purified ENO1 by Western blotting. These results revealed
heterogeneity across several patients in their anti-ENO1 serum immunoreactivity.
The true clinical value/advantage of using serum autoantibodies as a biomarker has been
recently called into question. Unfortunately, many published studies on TAA identification have
failed to ascertain the relevance of the TAA to the tumor progression or disease prognosis. Since
67 serial serum samples from 24 OS patients were available at a wide range of time period (ranging
0 to 400 days after diagnosis), we consequentially examined whether anti-ENO1 autoantibody
levels might change along the disease progression or even prognosis. The presence of
autoantibodies to ENO1 was assessed by ELISA over time in the serially collected at three time
points: diagnosis, before surgery and after surgery. The OD value of before and after surgery were
the average OD determined on serum that had been collected at a particular time point after surgery
during a month period (mean, 4.15 months). Interestingly, although there was no signification
association of ENO1 titers at these three time points, descant of ENO1 immunoreactivity was
observed in most patients along the disease progression, which may imply a potential association
between changes in anti-ENO1 autoantibody titers and disease progression. This may attribute to
the lack of adequate and sufficient serial samples for further in-depth analysis.
Anti-TAA autoantibodies might display heterogeneity in epitope recognition within a
given antigen. As a result, different patients may produce autoantibodies against either nondenatured epitopes or denatured epitopes. Consequently, the across-the-board of different assays
may enhance detection of specific autoantibodies in a particular cancer type. We have found an
incomplete correlation in the detection of anti-ENO1 antibodies between the different
immunoassays (ELISA, Western Blotting, and IIF). We proposed that the immunoreactivity to
ENO1 in OS could be indicative of aberrant expression of this protein in certain OS tumors. To
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further validate the identified TAA, we attempted to examine the ENO1 expression in OS tissue
specimens by immunohistochemistry. For these experiments, we used commercially available
human OS and chondrosarcoma tissue microarrays (TMA) which contain 51 paraffin-embedded
OS and chondrosarcoma tissue specimens with clinical stage and TNM grading. We observed that,
all of the osteosarcoma and chondrosarcoma specimens expressed the ENO1 protein, while on
normal bone tissues samples in the array did express the protein. Most of these showed strong
cytoplasmic and sporadically nuclear positivity (56 of 73, 76.7%). Unfortunately, because
osteosarcoma tissue specimens were not available in large numbers for this study, these was no
significant correlation between immunostaining density and histological characteristics including
clinical stage and TNM grading. The predominant elevation of ENO1 expression in OS compared
to normal bone tissue suggested that this protein might be upregulated during OS carcinogenesis.
This remains to be confirmed in a more complete analysis of ENO1 expression in other types of
bone tumor OS at different stages. To examine for specificity of ENO1 expression with regards to
cancer type, ENO1 expression level was compared with some other non-bone tumor tissues by
analyzing the data from the Human Protein Atlas. The Human Protein Atlas demonstrates the
feasibility of large-scale expression and purification of human antigens. Currently, the Human
Protein Atlas hosts over 41,000 MS-verified human protein fragments, representing more than
18,000 human protein-coding genes105. Most malignant cells exhibited moderate cytoplasmic and
occasional nuclear positivity111, which potentially implies the specificity of anti-ENO1
autoantibody might be higher in OS than other types of cancers. For instance, the Fig. 24 displays
ENO1 protein expression in Prostate cancer (PCa) and Lung adenocarcinoma (LUAD) tissues by
immunohistochemistry exhibiting moderate cytoplasmic positive staining.
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Figure 24: ENO1 protein expression in Prostate cancer (PCa) and Lung Adenocarcinoma
(LUAD) tissues by immunohistochemistry. A, Moderate staining of ENO1 expression in PCa at
400X magnification shows cytoplasmic and occasional nuclear positivity; B, Moderate staining of
ENO1 expression in LUAD at 400X magnification shows cytoplasmic and occasional nuclear
positivity.

4.4

Design customized TAA mini-arrays that could be used to enhance autoantibody
detection in OS.
Recent years have seen an enormous increase in efforts to exploit autoantigen arrays to

profile serum autoantibody responses in human disease as a result of their potential value for
enhancing early diagnosis, monitoring disease progression, identifying novel biomarkers, and
guiding interventions for disease prevention or early treatment. Compared to autoimmune diseases,
in which the presence of a particular autoantibody may have diagnostic value, anti-TAA
autoantibodies may exhibit a relative little diagnostic value for several reasons if evaluated
individually

25

. In general, the frequencies of autoantibodies specific for a particular TAA in a

certain cancer population are often relatively low, approximately about 10%-40%48,56,133.
Secondly, in that certain TAAs are engaged at tumorigenesis in various cancer types, a specific
autoantibody may present in different cancer types, which limits its application in clinical
diagnosis due to its inadequacy in discriminating between different cancer types. Thirdly, the lack
of specificity of some autoantibodies as a screening tool has also led to many possibly unnecessary
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diagnostic (biopsies) and therapeutic procedures, as a results of its high degree of complexity in
molecular events that are commonly associated with both cancer and other diseases associated
with inflammation and aging. In addition, the TAA array specific for a certain cancer type may
have a potential value for the development of cancer vaccines designed to boost the patient’s
immune system to fight the tumor. Moreover, certain TAA arrays could provide biosensor
representing that a unique cellular signaling pathway is being preferentially targeted by the
immune system in a given cancer type, indicating the highly association with the development of
malignancy. This notion could be applied for identifying novel targets for therapeutic interventions
or evaluating the effects of molecular targeting of components of that particular pathway in the
sensitization of tumor cells to death induced by already established therapeutic agents such as
antitumor drugs and radiation. Together, a critical unmet need in the diagnosis and management
of OS is the development of a TAA array to acquire the highest sensitivity and specificity.
The OS-related TAAs identified and validated in Specific Aims 1 and 2 were further
evaluated and customized in a TAA array for the specific detection of OS. Using ELISA multiplex
as our initial approach, we undertook a comprehensive analysis and evaluation of different
combinations of selected antibody-antigen systems to determine the optimal combination of TAAs
that yields the highest sensitivity and specificity of anti-TAA antibody detection in OS sera. As
controls, we used sera from individuals with normal human, patients with OC. Consequently, we
expect that in the selection of OS-associated antigens, some may tum out to be unique to OS and
others may not be specific. If an identified TAA can be validated as relatively specific for OS in
terms of frequency of autoantibodies in OS sera and elevated expression in OS tissue, then priority
will be given to that antigen for inclusion in the TAA mini-arrays for the immunodiagnosis of OS.
Since 5 (ENO1, GAPDH, TPI1, DENND4A, TUBA1C) of 20 proteins were identified successfully
from both of the two cell lines, we initially selected these five TAAs as candidate TAA array
antigens. However, when combined with the results of 1-D Western blotting, DENND4A (209KD)
and TUBA1C (50KD) were excluded from the list of candidate antigens for TAA array, because
of their low immunoreactivities against corresponding autoantigens in OS sera. And then, in order
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to get more widespread availability of TAA array to detect serum autoantibodies in OS patients,
we continuously focused on the proteins corresponding to the seven identified protein bands
(47KD, 33KD, 60KD, 37KD, 27KD, 17KD, 29KD), which were detected in both of these two cell
lines. However, further analysis of the autoantibody positivity to 27 KD and 50KD of Saos-2
cellular antigens in OS shows no significant difference with NHS leading to weed out the
corresponding proteins from the candidate list. Eventually, seven TAAs (ENO1, NPM1, GAPDH,
TPI1, HSP60, PDLIM1, and STMN1) were selected from the 20 identified proteins, which were
considered to be oncogenes, tumor suppressor genes, growth factors, or cell cycle-related proteins.
In addition to ENO1, we tested autoantibodies against the other 6 TAAs using individual
sera from 95 patients with OS, 28 sera from OC as well as 49 NHS. All of these 6 TAAs were
observed statistically significant increased autoantibody responses in patients with OS compared
to NHS, as well as no differences for the autoantibodies in OC and NHS groups. However, the
frequency of autoantibodies positive reactivity in OS sera against 4 of 6 TAAs (NPM1, GAPDH,
PDLIM1, and STMN1) was obtained to be significant higher than that in OC group. Using the
determined 7-TAAs array as a classifier, we were able to distinguish osteosarcoma from normal
human with a respectable 90.4% sensitivity and 85.7% specificity. The multiple-variable ROC
curve analysis by using the predictive probability variables of the 7-TAAs array also showed its
possible ability for discrimination the OS from OC and NHS. It should be noted that this TAA
array was relatively specific for cancer since the total autoantibody frequencies against the
combined TAAs were less than 15% for sera from normal controls. Ultimately, we attained a
highly specific and sensitive tailor-made TAA array (ENO1, NPM1, GAPDH, TPI1, HSP60,
PDLIM1, STMN1) that discriminate OS from benign bone tumor and normal human individuals,
when used for serological screening of antibody responses.
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Chapter 5: Conclusion and Future Study
5.1

Autoantibody against ENO1 could be a potential diagnostic biomarker
Osteosarcoma is the most frequently diagnosed malignant bone tumor and remains one of

the most harmful primary malignant tumors in childhood and adolescence, responsible for a high
rate of amputation, disability and death. Although the 5-year survival probability has increased to
almost 60% in recent years by combining neoadjuvant chemotherapy with surgical extirpation, the
progression and prognosis for patients with advance disease has remained grim. A critical need in
the diagnosis and management of OS is to determine a convincing combination of clinical
biomarkers that could detect tumors early with high sensitivity/specificity and with limited
invasiveness, and that could accurately predict which diagnosed patients will develop aggressive
tumors requiring treatment. Recent researches on the immune response to tumors provide a great
promise for developing new tools for the discovery of novel tumor biomarkers. These TAAs hold
the key to offer a new understanding of the molecular mechanisms associated with the skeletal
consequences of malignancy. Although data concerning the repertoire and function of TAA in OS
is still limited, increasing evidence suggests that these tumors might express several diagnostic
and/or therapeutic targets. The results of this study is eagerly anticipated.
To the best of our knowledge, this is the first study to report that certain patients with OS
produce autoantibodies to ENO1 and that this protein is notably highly expressed in OS tissues.
The identification and characterization of novel OS-associated autoantibodies targeting ENO1
from the glycolytic and plasminogen pathways provide a new promising tool to fine-tune early OS
diagnosis and management using minimally invasive methods, as well as enhance our
understanding of the immune system's role during OS tumorigenesis. Moreover, anti-ENO1
autoantibody level was potentially associated with disease progression in this subset of patients,
implying that this marker may be a further tool not only for diagnosing OS but also for disease
progression or even prognosis. Taken together, our results suggested that the autoantibody to
ENO1 might be considered as a potential serological biomarker for OS.
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5.2

Seven-TAAs array can improve sensitivity in diagnosis of OS
Although anti-TAA autoantibodies in OS may have limited diagnostic and prognostic value

when used individually, they have shown promise when profiled against carefully designed TAA
arrays25,101,134. These autoantibodies could also provide a platform for the development of novel
antibody-based immunotherapies for OS. In this study, we were able to dramatically increase the
frequency of positively reacting sera from 23.1% to 90.4% by adding 6 new candidate TAAs
(NPM1, GAPDH, TPI1, HSP60, PDLIM1, and STMN1) to ENO1 developing a novel 7-TAAs
array. The use of TAA arrays to profile the antitumor autoantibody response in a particular cancer
patient could also provide key information on disease progression, which could guide physicians
and patients in the making of important decisions regarding treatment options, combined with
other available clinical information.
5.3

Future directions
This study focuses on the recent advances in proteomic technology that have thrust the

skeletal cancer field into this exciting age of proteomics, and highlights the future work that is
required to adapt this technology to specifically interrogate the skeletal consequences of
malignancy. The findings represented in this study, while requiring further investigation in a large
scale of samples, support the growing evidence for differences in the immunobiology of
osteosarcoma compared with benign bone tumor and normal human. The present study has
provided strong evidence that the selective 7-TAAs array provide a promising and powerful tool
for enhancing cancer detection and treatment, but their utility in a clinical setting is currently in its
infancy. Before this TAA array could be widely applied in screening programs for OS diagnosis
or as a tool for monitoring tumor progression and guiding therapeutic interventions, it would be
essential to enhance their sensitivity and specificity by identifying novel TAAs and defining
systematically the optimal combination of TAAs. Different array platforms would also have to be
evaluated to determine which one yields the highest sensitivity with minimal experimental
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variation. Prospective studies in multiple clinical centers would then be required to ensure the
reproducibility of these arrays.
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SI- Staining intensity
SS-A- Sjogren's Syndrome A Control
TAAs- Tumor-associated antigens
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TEM1- Endosialin/tumor endothelial marker 1
TMA- Tumor microarray
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Supplemental File
Supplementary Figure 1: Peptide mass finger printing for spots S5 and S4.
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Supplementary Figure 2: Peptide mass finger printing for spots U4 and S6
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Supplementary Figure 3: Peptide mass finger printing for spots U6 and S8
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Supplementary Figure 4: Peptide mass finger printing for spots S11 and S9
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Supplementary Figure 5: Peptide mass finger printing for spots U7 and S16
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Supplementary Figure 6: Peptide mass finger printing for spots S19 and S17
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Supplementary Figure 7: Peptide mass finger printing for spots S21 and S20
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Supplementary Figure 8: Peptide mass finger printing for spots U12 and S23
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Supplementary Figure 9: Peptide mass finger printing for spots U29 and S24
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Supplementary Figure 10: Peptide mass finger printing for spots U14 and U13
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Supplementary Figure 11: Peptide mass finger printing for spots U25 and U2
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